

Index

- ABC *see* ATP-binding cassette
- ABC transporters 162–165, 177, 1310
- absorption, distribution, metabolism, and excretion (ADME) 652, 655, 670, 687, 688, 691, 692, 695, 715, 911, 913
- ACC *see* anterior cingulate cortex
- acenocoumarol 962
- acid
 - 10-tetraacetic 90
 - 3-phenyl-propionic 469
 - acetic 412
 - acetyl salicylic 959
 - aminobutyric 620
 - arachidonic 1119
 - co-glycolic 1221
 - diphenylmethoxyacetic 491
 - folic 115
 - formic 455
 - glucuronic 414, 1304, 1306
 - glutamic 1221
 - harmless orthosilicic 13
 - hydrochloric 145
 - lactic 469
 - lauric 67, 383
 - lithocholic 67
 - micro-ribonucleic 1250
 - monocarboxylic 161, 167
 - phenylalkanoic 394
 - phosphatidic 1222
 - pluronic 1216
 - polyglutamic 1218
 - propionic 456
 - ribonucleic 86, 164, 1200
 - tienilic 411, 1302
 - usnic 709, 718
- ACS *see* acute coronary syndrome
- activated protein C (APC) 616, 979
- active drug ingredients 141–148, 151
- active metabolite 410, 411, 414, 415, 456, 457, 459, 468, 471, 481, 492, 959, 1140, 1141, 1145
- active moieties 350, 452, 462, 463, 958
- activity
 - 21-hydroxylation 430
 - antidepressant 456
 - antiestrogenic 481
 - antihistamine 492
 - antiviral 417
 - physical 702, 1184, 1203
 - physiological 1214
 - preventive 1397
 - reductive 485
 - subnormal 1225
 - transporter 1312
 - vasodilating 478
 - wild-type 444
- acute coronary syndrome (ACS) 856, 859, 960, 961, 1117, 1118, 1143, 1144
- ADC *see* apparent diffusion coefficient

- adenosine diphosphate 162, 410, 412, 856, 1123–1125, 1127, 1128, 1130, 1153
- ADEs *see* adverse drug events
- adipocytes 1193, 1196, 1198, 1201, 1202, 1222, 1225, 1227
 - brown 1200
 - donor 1201, 1202
 - large 1200
 - mature 1197
 - small 1200, 1201
 - white 1200, 1201
- adipokines 1198, 1200, 1203
- adiponectin 1193
- adipose 27, 703, 1199, 1207, 1251
- adipose tissue 1174, 1175, 1183, 1191–1193, 1197, 1198, 1204
 - brown 1175, 1199
 - white 1175
- adipose tissue macrophages (ATMs) 1193, 1194
- adiposity 1180, 1183, 1191, 1197, 1199
- ADME *see* absorption, distribution, metabolism, and excretion
- adolescents 709, 830, 846, 878
- ADP *see* adenosine diphosphate
- ADP-induced platelet aggregation 857
- ADRIS *see* Adverse Drug Reactions Information Scheme
- ADROIT *see* ADR online information tracking
- ADR online information tracking (ADROIT) 738
- ADR ontology 731, 744–751, 753, 754, 758, 764
- ADRs
 - azathioprine-related 920
 - emergence of 895, 914, 921, 923, 925, 926, 934
 - fatal 921
 - incidence of 921–923
 - preventing 364
 - proportional 738
 - severe 354
 - severity of 355, 921
- ADRs *see* adverse drug reactions
- adults 343, 352, 363, 396, 692, 846, 1180, 1255, 1363
- adverse drug events (ADEs) 731, 793, 955, 966, 995, 1443, 1464, 1466
- adverse drug reactions (ADRs) 192, 343–347, 350, 363, 364, 727–731, 733–735, 739–741, 744, 745, 749–751, 762, 766, 767, 771–774, 903, 904, 922, 923, 1336, 1337
- Adverse Drug Reactions Information Scheme (ADRIS) 766
- Adverse Event Reporting System (AERS) 733, 737, 738
- adverse events 40, 191, 192, 196, 199, 201, 225, 652, 653, 759, 760, 789–791, 802, 957, 958, 1118, 1453, 1454
- azathioprine-related 806
- drug-related 727
- episodes of 779, 781
- mechanism-based 711, 725
- rare 652
- risk of 612, 788, 803, 824, 1354, 1357
- AERS *see* Adverse Event Reporting System
- AFP *see* alpha-fetoprotein
- African Americans 344, 356, 383, 386, 388, 408, 409, 425, 442, 445, 448, 826, 858, 870, 871, 874, 978, 979
- African descent 408
- African origin 40
- African populations 351, 449, 965, 968

- Africans 384, 386, 408, 409, 449, 494, 967, 969–971, 973, 975–977
- agents active antitumor 709
- antibacterial 1295
- antiemetic 479
- anti-fungal 424
- antihistamine 491
- antihypertensive 428
- antimicrobial 1321
- antitussive 428
- boron-rich 109
- chemotherapeutic 1361, 1455
- contrast-enhancing 15
- gadolinium 85
- infectious 1225
- nitrogen mustard alkylating 4
- oral hypoglycemic 400
- pathogenic 181, 749
- prophylactic antimalarial 417
- resistance-blocking 175
- sulfonylurea hypoglycemic 400
- superparamagnetic 17
- Age-Related Eye Disease Study (AREDS) 1339
- agonists 69, 957, 1119, 1124, 1125, 1127, 1128
- estrogen 480, 483
- platelet 1119
- algorithms 32, 183, 251, 304, 308, 326, 328, 624, 706, 761, 874, 962, 1350
- clinical dosing 874
- computer 1442
- genomic 929
- intelligent 292
- machine-learning 259
- modern fitting 689
- signal detection 763
- allele carriers 353, 354, 356, 360–362, 392, 960, 1306
- allele frequencies 407, 448, 611, 967, 974, 976, 978, 1312
- allele homozygotes 353, 354
- alleles
- hypomorphic 1181
- minor 1309
- rare 1175
- allelic variants 350, 377, 385, 393, 494, 496, 967, 972, 976, 1303
- Alliance for NanoHealth (ANH) 38
- allogeneic stem cell transplants 1252–1254
- allogeneic transplants 1253, 1254
- alpha-fetoprotein (AFP) 22, 23, 51
- alterations
- epigenetic 613–615
- functional 193, 202, 213
- transmissible 1178
- Alzheimer's disease 42, 109, 294, 394, 465, 466, 676, 922, 1385
- amino acids 90, 161, 167, 168, 377, 403, 425, 426, 445, 615, 623
- branched-chain 168
- free 1214
- mutated 623
- amiodarone 468, 475, 874, 982, 985
- amitriptyline 403, 423, 431, 449–451
- amoxicillin 421
- amygdala 358–362
- angiogenesis 15, 28, 65, 97, 1200, 1220, 1227
- ANH *see* Alliance for NanoHealth
- animal models 62, 100, 155, 394, 431, 686, 907, 1173, 1180, 1189, 1216, 1222, 1307
- ANNs *see* artificial neural networks
- antagonists 386, 480, 709, 1151
- nonpeptidic 479
- P2Y12 receptors 1151
- propylamine H1-receptor 492
- anterior cingulate cortex (ACC) 358–361, 371
- antiarrhythmic agent 468, 470, 472

- antiarrhythmic drugs 467, 468, 473, 475, 1303
- antiarrhythmics 345, 347, 429, 468, 625
 - class II 468
 - class III 468
- antibiotics 28, 1446
- antibodies 13, 20–22, 64, 68, 71, 114, 116, 151, 185, 475, 917, 958, 1212–1214, 1224
- antimitochondrial 1299
- antinuclear 1299
- antismooth muscle 1299
- fluorescence-labeled 28
- single-chain 69
- therapeutic 1207
- anticancer drugs 5, 28, 164, 167, 378, 625, 709
- anticoagulants
 - coumarin 386
 - oral 868
- antidepressant drugs 835, 936
- antidepressants 182, 344, 345, 347, 350, 352, 354, 359, 360, 403, 423, 459, 934–936
 - nontricyclic 428
 - serotonergic 458
 - tetracyclic 458
- antidepressant treatment 342, 359, 360, 362
- antiemetics 429, 479, 491, 625
- antiplatelet agents 410, 1119, 1126, 1143, 1144, 1146, 1148, 1153
- antiplatelet drugs 860, 959, 960, 1119, 1125, 1126, 1132, 1135, 1136, 1150
- antiplatelet effects 1123, 1126, 1128, 1142, 1143, 1145, 1148
- antiplatelet therapy 1117, 1118, 1126, 1132, 1144, 1145, 1152, 1153
 - dual 857, 1118, 1134, 1145, 1149
 - tailored 1147, 1152
- antipsychotic drugs 460, 464, 966, 1183
- antipsychotics 182, 350, 352, 356, 459, 460, 462, 463, 491, 625, 934
- antiretroviral therapy 624, 878
- APC *see* activated protein C
- apoptosis 74–76, 132, 133, 245, 270
- apparent diffusion coefficient (ADC) 107
- approaches 21, 68, 99, 100, 116, 172, 207–209, 211–214, 658, 659, 679, 680, 686, 690–692, 745, 746, 860, 1215, 1390–1392
- automated 312
- clinical 1297
- consensus-based 1390
- current 802, 1179, 1373
- deliverable-based 660
- drug-centered 1348
- drug-centric 1355
- evidence-based 83, 1340
- inductive 1418
- integrative 894
- interdisciplinary 929
- iterative 794
- lab-on-chip 917
- mathematical 198, 931
- mechanism-based 954
- methodical 657
- model-independent 1275
- multistage 15, 44, 45
- nonparametric 761
- one-size-fits all 82
- pluralistic 816
- probabilistic 1418
- resequencing 181
- rights-centered 817
- semiparametric 328
- signature 277
- simulation 924
- social 816
- standard-of-care 625

- systems-based 222, 251, 252
- theranostic 917
- top-down 689
- translational 207
- trial-and-error 323, 341, 342
- unfocused 657
- apripidine 429, 468, 475, 476
- apririn reaction units (ARUs) 1124
- aptamers 13, 21, 28, 68, 72
- AREDS *see* Age-Related Eye Disease Study
- ARIES *see* Atazanavir Ritonavir Induction/Simplification with Epzicom Study
- aripiprazole 459, 460, 464
- arrays 22, 81, 88, 171–174, 251, 1389, 1424
 - GeneChip expression 181
 - liquid-phase 173
 - microbased particle 173
 - SNP 1322
 - two-color 617
- artificial neural networks (ANNs) 211
- ARUs *see* apririn reaction units
- ASDs *see* autism spectrum disorders
- Atazanavir Ritonavir Induction/Simplification with Epzicom Study (ARIES) 849
- ATMs *see* adipose tissue macrophages
- ATP-binding cassette (ABC) 162, 207, 1309
- autism spectrum disorders (ASDs) 362, 374
- azathioprine 626
- barriers 9, 10, 12, 111, 152, 198, 205, 251, 430, 669, 670, 1458–1460, 1462
 - anatomical 62
 - biochemical 151
 - biological 14, 121
 - blood–brain 110, 121, 164
 - blood–cerebrospinal fluid 110
 - cellular 59, 1214
 - domain 214
 - intestinal epithelial transport 1215
 - protective 1370
 - semipermeable 110
- BAT *see* brown adipose tissue
- Bayesian approaches 707, 738, 1275, 1286
- Bayesian fit 1288
- Bayesian method 382, 707, 756, 761, 762, 1288, 1289
- BBB *see* blood–brain barrier
- BCRP *see* breast cancer resistance protein
- BDNF *see* brain-derived neurotrophic factor
- behavior 171, 204, 924, 928, 933, 1180, 1189, 1340, 1360, 1366, 1389, 1396, 1417
 - biological 29
 - compound's 161
 - concentration-dependent 930
 - customer 1416
 - distributional 324
 - dynamic 194, 331, 336
 - ethical 816
 - feeding 1203
 - human 1445
 - interactive 203
 - paramagnetic 15
- bile salt export pump (BSEP) 166, 1310
- bioavailability 17, 28, 141–144, 146–148, 151, 155, 160, 175, 185, 393, 453, 465, 469, 470, 697, 698
- biobarriers 9, 10, 12, 14
- bioinformatics 8, 183, 198, 236, 292, 313–319, 607, 633, 907, 908

- biological processes 210, 260, 281, 305
- biological systems 31, 194, 209, 322, 324, 331, 719
- biologics 38, 192, 195, 631, 663
- biomarkers 18, 24, 25, 33, 195, 196, 204, 238, 239, 345–348, 609–612, 617, 619, 620, 630–632, 636, 637, 1187, 1188
 - classical 1228
 - conditional 280
 - early 99, 107
 - epigenetic 613–616
 - hepatic 177, 178
 - metabolomic 620, 621
 - multivariant 259, 261
 - proteomic 618
 - single-gene 259
 - systemic 214
 - systems-based 214
 - transcriptomic 616–618, 630
- biomaterials 29, 30, 66, 1222, 1223
 - human 1338
 - natural 71
- biotransformation 472, 959, 1295
- black-box warning 675, 846, 861, 868, 1296
- bleeding complications 387, 960, 961, 1118, 1126, 1134, 1145, 1146, 1148, 1153
- bleeding risk 397, 860, 1152
- blood 24, 44, 287, 621, 653, 697, 698, 701, 1124–1126, 1272, 1273
- blood–brain barrier (BBB) 110, 111, 116, 121, 164
- blood cells 225, 495, 626, 627, 693, 694, 698, 970, 1250
- blood flow 147, 325, 467, 701, 703
- blood glucose 401, 1222, 1223, 1228
- blood pressure 326, 478, 1353
 - diastolic 392, 478
 - lower systolic 392, 479
- blood samples 227, 495, 624, 654, 1272, 1279, 1289
- blood vessels 30, 62, 65, 1198, 1204
- BNCT *see* boron neutron capture therapy
- body 5, 9, 15, 27, 63, 64, 69, 93, 114, 698–700, 702, 703, 908, 910, 926, 930–934
 - authoritative 806
 - ciliary 1177
 - decision-making 797
 - foreign 627
 - human 157, 194, 323, 324, 336, 686, 692, 816
 - patient's 321
- body fluids 616, 620, 698
- body weight 63, 117, 118, 388, 711, 714, 955, 962, 995, 1180, 1191, 1455
- bone 26–29, 89, 703, 1249, 1251, 1260
 - bone marrow 4, 5, 27, 89, 626, 1249, 1254–1256
- boron 113–119, 124–126
- boron neutron capture therapy (BNCT) 109–114, 116, 118, 120, 122–126
- brain 110–112, 121–123, 168, 206, 362, 376, 415, 425, 426, 430, 467, 703–705, 1191, 1192, 1198
 - human 425, 426, 620
- brain activity 360
- brain cancer 109
- brain cells 467
- brain-derived neurotrophic factor (BDNF) 360, 1263
- brain diseases 109
- brain infections 110
- brain metastases 110
- brain parenchyma 359

- brain responses 1189
- brain tumors 90, 97, 99, 113, 114
- breast cancer 43, 225, 226, 264–266, 273, 274, 480, 485, 486, 1393, 1457
 - advanced 853
 - early-stage 4
 - estrogen-positive 618
 - estrogen-receptor-positive 629
 - metastatic 480, 958, 1321
 - metastatic
 - HER2-overexpressing 851
- breast cancer cells 68, 167, 619, 1260
- breast cancer patients 236, 618, 621, 785, 936, 1393
- breast cancer prevention 480
- breast cancer recurrence 936
- breast cancer resistance protein (BCRP) 163, 164, 166, 908
- breastfeeding 865
- breastfeeding mothers 488
- brown adipose tissue (BAT) 1175, 1189, 1196, 1199, 1200, 1202
- BSEP *see* bile salt export pump
- bufuralol 426, 428, 431, 443, 445, 447, 476
- bufuralol hydroxylation 444

- CABG *see* coronary artery bypass graft
- CAD *see* coronary artery disease
- cancer
 - battle 30
 - breast 851, 852
 - cervical 616
 - colon 227
 - colorectal 286, 612, 613, 627, 638–640, 958, 1352
 - endometrial 487
 - gastric 851
 - liver 227
 - lung 271
 - ovarian 14, 65, 878
 - pancreatic 5, 1355
 - prostate 5, 68, 1342, 1354, 1361
 - prostatic 1177
 - thyroid 90
- cancer biology 245
- cancer biomarkers 16, 17, 21
- cancer cells 5, 13, 44, 68, 113, 167, 183, 854, 1227
- cancer patients 30, 88, 101, 130, 183, 236, 247, 249, 1263, 1361
- cancer therapy 42, 135
- cancer treatment 820, 1396, 1457, 1460
- cardiac stem cells (CSCs) 1257
- cardiac surgery 411
- cardiovascular diseases 24, 195, 196, 203, 238, 1145, 1153, 1172, 1174, 1203, 1383
- cardiovascular events 859, 960, 961, 1140, 1144, 1149
- care pathways 791, 794, 801, 803–805
 - clinical 795, 803
 - complex 804
 - multiple 804
 - relevant 804
- carriers 14, 63, 64, 349, 353–356, 360, 362, 384, 387, 388, 398, 470, 860, 1142, 1148, 1149, 1321, 1322
- efflux 168
- heterozygote 382
- cartilage 27–29, 1251, 1257
- carvedilol 428, 468, 476, 478, 983
- case report forms (CRFs) 733
- Caucasian population 410, 863, 956, 965, 970, 974
- CBA *see* cost-benefit analysis
- CBER *see* Center for Biologic Evaluation and Research
- CCD *see* charge-coupled device

- CDER *see* Center for Drug Evaluation and Research
- CDISC *see* Clinical Data Interchange Standards Consortium
- CDRH *see* Center for Devices and Radiological Health
- CDS *see* clinical decision support
- CDSs *see* computerized decision support systems
- CEA *see* cost-effectiveness analysis
- celecoxib 166, 378, 396–398
- cell cytoplasm 60–62
- cell membranes 111, 151, 162, 701
- cells
- B-lymphoblastoid 493
 - cancerous 112
 - cancer-resistant 162
 - diseased 1224, 1225, 1339
 - excretory 164
 - germ 613
 - glial 426
 - glioblastoma U87 116
 - healthy 5, 113
 - hematopoietic 1193
 - insect 383, 412, 425, 444
 - malignant 112, 113
 - mesodermal 1249
 - mouse lymphoma 98
 - mucosal 152
 - multidrug-resistant 165
 - myeloid 1194
 - neuronal 1251
 - parental 429
 - parietal 145
 - peripheral 1203
 - phagocytic 63
 - pyramidal 426
 - red 699, 702
 - reticuloendothelial 62
 - skin 1339
 - transplanted 1262
 - tumor 12, 69, 113, 183, 1254, 1393
- cell types 28, 44, 624, 1175, 1195, 1251, 1339
- adult 1249
 - mammalian 1225, 1258
- cellular level 168, 194, 203, 1195, 1262
- Center for Biologic Evaluation and Research (CBER) 35, 37, 631
- Center for Devices and Radiological Health (CDRH) 35, 37, 631
- Center for Drug Evaluation and Research (CDER) 35, 37, 631, 632, 656
- central nervous system (CNS) 110, 121, 283, 428, 463, 470, 488, 1190, 1218
- cetuximab 612, 613, 958
- charge-coupled device (CCD) 100, 1430
- chemotherapy 11, 12, 69, 98, 479, 618, 622, 624, 850, 852, 853, 855, 1393
- adjuvant 227
 - concurrent 14
 - cytotoxic 1455
 - systemic 91
- chemotherapy drugs 182, 803
- chemotherapy regimen 803
- CHF *see* congestive heart failure
- Chinese patients 352, 392, 393, 489
- Chinese population 384, 408, 410
- Chinese subjects 395, 443
- chlorpheniramine 429, 491–493
- chlorpromazine 428
- cholesterol 67, 72, 114, 117–120, 1222
- cholinesterase inhibitors 464, 465
- chromosome 287, 349, 352, 354, 403, 425, 968, 1178, 1314, 1322
- chronic diseases 1382, 1383, 1387, 1396, 1446

- biggest-four 222
- common 835
- cilostazol 1149
- cimetidine 345, 347, 348, 475, 721
- circulation 9, 66, 110, 112, 1213, 1214
 - enterohepatic 705
 - systemic 142–144, 149, 150, 399, 697, 698
- cirrhosis
 - advanced 227
 - chronic hepatic 472
- citalopram 345, 352, 354, 358, 422, 454–456, 980, 981, 983–987
- clarithromycin 421
- classes 25, 86, 162, 163, 303, 345–348, 413, 423, 468, 470, 472, 473, 609, 625, 707, 745, 747
 - biguanide 417
 - compound 1211
 - cytosolic GST 1307
 - ethanolamine 491
 - opioid 867
 - pharmacological 934
 - protein 264
- clearance 112, 348, 349, 386, 393, 394, 398, 413, 414, 430, 431, 459–461, 463, 464, 470, 473, 493, 494, 696, 697, 1219, 1273
 - baseline 425
 - creatinine 349, 702
 - drug's 696
 - fast blood 114
 - lidocaine 470
 - lornoxicam 395
 - oral 431, 470
 - organ 700
 - pheno-barbital 413
 - whole-organ 701
- clinical applications 27, 357, 831, 835, 911, 955, 961, 1225, 1262
- clinical assessment 388, 1293, 1294, 1296, 1298, 1300, 1302, 1304, 1306, 1308, 1310, 1312, 1314, 1316, 1318
- clinical care 17, 32, 221, 222, 236, 252, 937, 1337, 1342, 1346, 1362, 1372
- clinical data 19, 30, 32, 197, 199, 208, 231, 233, 234, 237, 306, 689, 691, 707, 711, 1413
- Clinical Data Interchange Standards Consortium (CDISC) 229, 1413, 1430
- clinical decision support (CDS) 32, 205, 231, 251, 637, 767, 768, 1340, 1358, 1402, 1418, 1461
- clinical errors 199, 201
- clinical evidence 8, 483, 846, 961, 996, 1259
- clinical guidelines 915, 934, 1402, 1442, 1456, 1457, 1461, 1463
- clinical knowledge 902, 924, 1389–1391, 1394, 1399, 1413–1415, 1418–1420, 1422, 1424–1426, 1464
- clinical outcomes 23, 227, 237, 239, 364, 766, 805, 1273, 1274
 - better 191, 192, 197, 1147
 - direct 1446
 - poor 857
 - superior 1446
- clinical pathways 788, 801
- clinical trials
 - early-stage 113
 - first 649
 - international 210
 - next-phase 661
 - prospective 794, 905, 921, 929
 - robust 792
 - small-scale 87

- successive 648
 - clinical utility 34, 87, 251, 631,
 - 673, 674, 800, 820, 829, 836,
 - 846, 874, 875
 - potential 1125
 - practical 900
 - clomipramine 423, 428, 449, 452, 981, 1314
 - clopidogrel metabolism 1137, 1140, 1144, 1148
 - clopidogrel response 856, 858, 1128, 1140, 1142, 1144, 1151
 - clozapine 347, 354, 362, 364, 460, 982, 985, 987
 - CNS *see* central nervous system
 - complex diseases 179, 198, 239,
 - 636, 900, 910, 913, 1229,
 - 1340, 1344, 1345, 1348, 1367
 - computerized decision support systems (CDSSs) 209, 1441, 1442
 - computerized provider order entry (CPOE) 1402, 1441, 1442
 - computer tomography (CT) 85, 93, 1189, 1299, 1399
 - congestive heart failure (CHF) 390, 393, 472, 478, 1343, 1360, 1394
 - coronary artery bypass graft (CABG) 1134
 - coronary artery disease (CAD) 1127, 1351, 1354, 1383
 - correlation 134, 151, 159–162, 200, 213, 277, 278, 305, 306, 770, 870, 871, 1198
 - clinical 934
 - functional 258, 312
 - genotype–phenotype 203, 213
 - nonlinear 160
 - poor 160
 - positive 277, 358
 - significant 450, 461, 470, 1366
 - strong 849
 - weak 463
- cost-benefit analysis (CBA) 780, 787, 788
 - cost-effectiveness 364, 779, 784, 792, 793, 796, 805–808, 875, 878, 921, 929, 996, 1397
 - cost-effectiveness analysis (CEA) 21, 114, 780, 784–786, 791, 792, 796, 801, 878, 920
 - cost utility analysis (CUA) 780, 784–786, 791, 796, 797
 - covariates 327, 685, 687, 691, 696, 697, 1284, 1289
 - CPOE *see* computerized provider order entry
 - CPOE system 1461, 1463
 - CRFs *see* case report forms
 - Crohn’s disease 626
 - CSCs *see* cardiac stem cells
 - CT *see* computer tomography
 - CUA *see* cost utility analysis
 - cure rates 421
 - cytokines 27, 66, 1252, 1255–1257, 1302, 1313
 - cytoplasm 67, 132, 1202, 1208, 1213, 1222, 1225, 1227
 - cytotoxicity 429
- DAG *see* direct acyclic graph
 - data
 - clinical trial cohort 664
 - complex 212
 - compound-specific 694
 - controversial 1134
 - critical 1407, 1422
 - decoupling 1412
 - demographical 1316
 - disaggregated 802
 - drug-related 910, 926
 - dynamic 230
 - epigenomics 206
 - experimental 157, 687, 713, 899, 924
 - familial health 823

- genetic 212, 231, 819, 824, 1346
- genome-wide 205, 218
- glycoproteomic 227
- haplotyping 902, 906
- health-related 1403
- heterogeneous 207, 1454
- histopathological 83
- human clinical trials 633
- medication 1403, 1407
- metabolomic 238
- microcost 784
- molecular 226, 234
- multidimensional 292
- numerical 729
- observational 1459, 1460
- observed 689, 707, 712, 738
- patient-level 784
- patient-recorded 1414
- pharmacogenomic 34, 630, 633
- phenotype 237, 928
- population 708
- preprocessed 633
- published 240, 243, 715
- raw sequencing 232
- system 704
- therapeutic drug-monitoring 714
- time-motion 210
- toxicological 155
- ximelagatran 1320
- databases 197, 203, 207, 217–219, 225, 230, 232, 237, 238, 240–242, 245, 292, 690, 728, 729, 732–741, 1348, 1349
- company 732
- comprehensive 694
- manually curated 237
- multidimensional 209
- national 760, 763
- online biomedical 298
- public 928
- data coordination centers (DCCs) 228
- data elements 235, 733
 - clinical 238
 - common 733
- data integration 199, 204–206, 209, 217–219, 228, 1421, 1423
- data management 197, 198, 211, 214, 633, 737
- data mining 205, 250, 308, 770, 1411, 1424
- data mining applications 197
- data mining approaches 205, 771, 775
- data mining methods 211, 767, 770
- data mining techniques 206, 214, 293
- data sets 225, 231, 232, 238, 244–247, 249, 260, 271, 272, 274, 299, 301, 303–307, 310, 1282, 1283, 1285, 1375
 - clinical 242
 - cohesive 272
 - comprehensive 195
 - dummy 266
 - experimental 243
 - glycomics 234
 - independent 196
 - integrated 236, 237
 - large 249, 257
 - longitudinal 1183
 - medium 647
 - molecular 227
 - phenotypic 1361
 - primary 928
 - private 237, 247
 - proteomic 232
 - rectal cancer 205
 - toxic response 271
 - trial design 693
- data sources 206, 225, 312, 313, 791
- data storage 231, 233
- DCCs *see* data coordination centers

- DCs *see* dendritic cells
- death 182, 192, 345, 618, 728, 834, 852, 865, 915, 921, 922, 966
 all-cause 959
 cellular 132
 million 227, 1171
 premature 1172
- debrisoquine 427, 428, 431, 443, 453, 458, 476
- decision makers 779, 784–786, 788, 792, 795, 796, 798, 804, 1394, 1400, 1422
- decision-making process 32, 87, 205, 206, 209, 210, 214, 797, 1424
- decision support 197, 198, 204, 206, 208–210, 212, 214, 1411, 1422, 1423, 1441, 1442, 1445, 1446, 1455, 1456, 1465
 clinical 32, 767, 1402, 1418, 1440
 effective 234
 successful 210
- decision support functions 199, 209
- decision support systems (DSSs) 201, 210, 768, 1441, 1451, 1453
- decision support tools 251, 768, 1340, 1358, 1392, 1443, 1446
- defects 182
 potential birth 1363
- deficiency, vitamin B12 422
- DEGs *see* differentially expressed genes
- dendritic cells (DCs) 70, 1194
- deoxyribonucleic acid (DNA) 5, 22, 23, 116, 172–174, 266, 326, 384, 483, 609–611, 615–617, 627, 628, 768, 901, 1226, 1227, 1338
- depression 109, 346, 353, 358, 359, 449–451, 453, 488, 922
 anxious 360, 373
 late-life 342, 359, 362
 respiratory 862
- depression chronicity 359, 360
- description logics (DL) 744, 746, 747, 763, 774
- desipramine 428, 431, 449, 451, 470, 475
- detection 17, 19–23, 30, 44, 97, 173, 239, 728, 729, 731, 1382, 1383, 1392, 1393, 1395, 1396
 biomolecular 22, 51
 clinical 1392, 1393
 error 228
 millimolar-level 85
 multiplexed 21
 nanoscale motion 22
 noninvasive 16, 44
 single-molecule 23
- devices 19, 22, 23, 35–38, 45, 816, 1216, 1413
 analytical 19
 charge-coupled 100
 DNA diagnostic 23
 handheld 1404
 implantable miniature 45
 miniature 45
 mobile 1410
 nanofluidic 22
 patient-monitoring 1408
 remote monitoring 1409
 testing 1126
- dextromethorphan 428, 431, 444, 445, 474, 712, 1303
- diabetes mellitus (DM) 683, 961, 1143, 1144, 1397
- diagnosis
 accurate 98, 195, 200, 214, 1298, 1384, 1415
 clinical 19, 213, 617, 848, 849
 current 1373
 customize 495
 genotype-guided 1375
 histologic 225

- incomplete 1391
- in-time 1172, 1228
- molecular 906, 1184
- personalized 313, 1185, 1187, 1206
- reliable 1187
- sensitive 616
- differentially expressed genes (DEGs) 258, 270, 271, 281, 287
- differentiation 678, 851, 1197, 1202, 1256
 - adipocyte 1198
 - cellular 171
- diffusion-weighted imaging (DWI) 99, 107
- DILI
 - lumiracoxib 1322
 - ximelagatran 1322
- DILI *see* drug-induced liver injury
- DILI development 1294, 1297, 1305–1307, 1311, 1313, 1315, 1324–1326
- DILI diagnosis 1297–1299
- DILIN *see* drug-induced liver injury network
- DILI patients 1296, 1302, 1307, 1309, 1314
- DILI research 1294, 1299, 1310, 1325, 1326
- DILI susceptibility 1293, 1309, 1312, 1314
- diphenhydramine 429, 491
- direct acyclic graph (DAG) 304
- direct-to-consumer companies (DTC companies) 33, 835, 836, 1371
- disease management 88, 95, 1185, 1397, 1442
- disease mechanisms 200, 204, 1187, 1229
- disease pathophysiology 901, 921, 926, 927
- disease pathways 2, 179
- disease prevention 676, 1409
- disease processes 9, 17, 129, 200, 495
- disease progression 18, 24, 180, 628, 852, 1194, 1337
- disease risk 32, 33, 221, 934, 1340, 1344, 1347, 1348, 1352, 1359, 1362, 1373
- diseases
 - acid-related 962, 964
 - atherosclerotic 411
 - atherosclerotic 196, 216
 - autoimmune hematologic 1250
 - blood vessel 272
 - civilization 1228
 - complex trait 1325
 - concomitant 631, 1297
 - destructive 26
 - enriched 272
 - heterogeneous 273
 - homeostasis-changing 266
 - hypersecretory 418
 - infectious 9, 22, 23, 180, 181
 - joint 1174
 - later-stage 44
 - leukocyte-implicated 69
 - leukocyte-implication 70
 - lifelong 1172
 - life-threatening 824
 - major 1171
 - mediastinal 92
 - motor neuron 1339
 - mucosal 62
 - multiple 284, 1385
 - neurological 196, 1339
 - patient's 1185
 - peripheral vascular 410
 - pulmonary 1299
 - rare 636, 675, 835
 - respiratory 196, 283
 - reverse 1395
 - stable 11
 - thromboembolic 868
 - untreatable 43

- urogenital 272
- disease states 83, 171, 259, 702, 868, 875
- disease subtypes 616, 652, 675
- disorders 81, 84, 748, 749, 770, 1177, 1247, 1254, 1337, 1364, 1370, 1383
- anxiety 353, 368
- autism spectrum 362, 374
- autoimmune 626
- bipolar 620, 1365, 1366
- common 1179
- complex 845
- degenerative 1250
- depressive 455, 456
- flavism 899
- functional 748, 749
- hemorrhage-related 752, 753
- laceration-related 753
- major depressive 342, 371–373
- metabolic 201
- miscellaneous 4
- mood 455, 1361, 1365, 1366
- neural 1251
- nutrition 735
- physiological 110
- psychiatric 357
- psychological 238
- psychotic 357
- renal and urinary 735
- schizoaffective 349, 350, 355
- sex differentiation 272
- single-gene mutation 845
- tubular 735
- urea cycle 621
- ventricular antiarrhythmic 468
- disproportionality 737–739
- distribution
 - adipose 1197
 - empirical 309
 - ethnic 378, 403, 408
 - fat 1184, 1196, 1197
 - haplotype 384
 - interethnic 409
- log-normal 1281
- nonparametric 1280
- nonuniform 1375
- normal 327, 330, 1278–1281, 1287
- parametric 1278
- Poisson 738
- posterior 1286
- probability 1286
- protein class 265
- statistical 1280
- systemic 1228
- DL *see* description logics
- DM *see* diabetes mellitus
- DNA *see* deoxyribonucleic acid
- DNA microarrays 19, 173, 179, 617, 630, 633, 867
- DNA samples 650–654, 683, 822, 1339
- DNA sequences 179–181, 611, 613, 996
- domains 81, 86, 97, 100, 163, 193, 197, 200, 208, 309, 715, 754
 - extracellular 850
 - functional 222, 235
 - independent quality 1457
 - ligand-binding 60
 - public 236
- donepezil 464, 465
- dopamine 355, 430, 453
- dosage forms 141, 142, 144, 146, 161, 687, 1217
 - aqueous suspension 142
 - gelatin capsule 143, 144
 - liquid 146
 - oral 141, 142
 - solid 146
 - solid oral 146
 - uncoated tablet 143
- dose
 - administered 474, 481, 1271, 1272
 - aspirin 1146
 - complete 182

- correct 95
- efavirenz 711
- effective 626
- escalating 639
- excreted 459
- high-maintenance 1147
- imipramine 349
- initial 851, 1274, 1289, 1452
- internal 703
- intravenous 14
- lethal 112
- medication 342
- nominal 1289
- optimal 1146
- PPI 964
- radioactive 471
- right 607, 962, 964, 996, 1336
- single 395, 416, 422, 451, 452, 462, 463, 490, 492, 710, 712, 863, 866, 963
- stable 389, 868, 872
- standard medication 1300
- tolerated 996
- total 182, 391
- useful 118, 121
- dose adjustment 487, 712, 846, 916, 934, 935, 967, 1272, 1273
- dose requirements 389, 691, 873, 955
- doxorubicin 6, 9, 10, 12, 166, 167, 287, 1221
- drug absorption 145, 146, 148, 151, 156, 161, 185, 323, 337, 711, 923
- drug administration 9, 182, 192, 251, 257, 323, 330, 344, 465, 480, 607, 1272, 1273
- drug carriers 111, 116, 130, 1217
- drug classes 5, 625, 936, 1172, 1208, 1211
- drug clearance 351, 352, 375, 377, 398, 496, 687, 931
- drug concentrations 160, 324–326, 331, 622, 866, 1272, 1275, 1277, 1286
- drug delivery 1, 10, 11, 30, 45–47, 59, 81, 109, 111, 121, 129, 141, 905, 1219, 1220
 - oral 141, 142
 - personalized 337
- drug delivery systems 29, 43, 185, 925
- drug development 609, 610, 644–650, 654–656, 658, 664–666, 670–676, 680–682, 819, 1291, 1466
 - modern 156
 - new 183, 222, 727, 902, 905, 913, 915, 925
 - phases of 767, 1286
 - preclinical 686
- drug development process 178, 648, 654, 658, 670, 673, 676, 715, 827, 909
- drug development team 648, 660, 662, 665, 676
- drug discovery 100, 178, 179, 193, 195, 199, 200, 209, 248, 258, 704, 708, 1209, 1210
 - better 210
 - modern 1209, 1211, 1212
 - new 899, 911
 - potential 202
 - preclinical 687
 - traditional 1209
- drug disposition 284, 377, 703, 767, 838
- drug distribution 325, 698, 699, 703, 704, 908
- drug–drug interactions 688, 692, 709, 714, 850, 954
- drug efficacy 321, 337, 343, 344, 377, 619, 656, 845, 914, 916, 925, 932, 1339
- drug-induced adverse effects 130
- drug-induced hepatotoxicity 1293

- drug-induced liver injury (DILI)
 - 911, 1293–1297, 1300–1309, 1311, 1313–1316, 1320–1326
- drug-induced liver injury network (DILIN) 1295, 1326
- drug interactions 324, 343, 344, 347, 348, 350, 364, 419, 614, 925, 926, 931, 934–936, 1145, 1441, 1442
- drug labels 251, 612, 675, 679, 683, 813, 996, 1188
- drug metabolism 121, 171, 323, 337, 375, 377, 384, 476, 494, 711, 712, 1300–1303, 1324
- drug-metabolizing enzymes 270, 280, 376, 495, 497, 691, 692, 700, 702, 923, 930, 1125, 1300
- drug molecules 5, 111, 112, 149, 150, 1217, 1219
- drug monitoring 423, 462, 495, 928, 933, 957, 996, 1272, 1273
- drug permeability 151, 156, 161
- drug prescription 893, 894, 896, 898, 900–902, 904, 906–908, 910, 912, 914, 916–918, 920–922, 924, 926–936
- drug products 37, 141, 142, 160, 610, 614
- drug reactions 321, 323, 363, 899, 931
- drug release 28, 39, 1220, 1221
- drug resistance 163, 165, 175, 180–182, 622, 623
 - antiretroviral 622, 623, 642
 - nucleoside 167
- drug response 202–204, 321–324, 326, 327, 336, 337, 377, 496–498, 675, 767, 821, 937, 954, 955, 998, 1344, 1345, 1348–1350
 - altered 905, 1341
 - antiplatelet 1118, 1126
 - differential 895
- drugs
 - active 151
 - administered 151
 - ampliplilic 111
 - antibody 612
 - anticonvulsant 389
 - antidepressive 957
 - antidiabetic 1190
 - antifolate 167
 - antihypertensive 826
 - antiretroviral 611, 622, 623
 - approved 609, 1187
 - associated 732
 - basic 473
 - blockbuster 636, 646, 675
 - candidate 685
 - causative 1324
 - clinical 231, 376, 378
 - commercialized 1295
 - concomitant 686, 692
 - culprit 1297
 - effective 45, 647, 648
 - encapsulate 1220
 - enhanced 29
 - experimental 824
 - free 700
 - generic 956
 - high-clearance 476
 - hydrophilic 111
 - loaded 917
 - love 429
 - low-clearance 476
 - low therapeutic index 387
 - marketed 921, 922, 1296
 - model 176
 - nonantiarrhythmic 915
 - novel 907
 - nucleoside 167
 - older 496
 - orphan 636
 - over-the-counter 492
 - personalized 182
 - pharmaceutical 494

- platinum 168
- polypeptide 1215
- potential 921
- potential human 632
- prescribed 827, 929, 1452
- reference 956
- safe 175
- secure 184
- soluble 147
- sulfonylurea hypoglycemic 400
- therapeutic 493
- water-insoluble 11
- water-soluble 1221
- drug targets 195, 196, 306, 646, 672, 767, 1209, 1214, 1376
- drug therapy 495, 497, 770, 845, 954, 1286
 - administered 1452
 - antipsychotic 496
 - pediatric 715
 - personalized 931
- drug toxicity 178, 265, 271, 321, 922, 1340
- drug transportation 161
- drug treatment 43, 135, 183, 358, 620, 937, 1272, 1439
- drug trials 651, 667, 770, 813, 831
- DSSs *see* decision support systems
- DTC companies *see*
 - direct-to-consumer companies
- DTC genetic tests 835
- DTC pharmacogenomic tests 835
- DTC problems 835
- DWI *see* diffusion-weighted imaging

- EBEs *see* empirical Bayes estimates
- economic evaluations 779–781, 783–785, 787, 788, 791–800, 802, 803, 805–806, 920
 - model-based 793, 795
 - prospective 792, 800
 - published 795, 798–800
 - secondary 799
 - trial-based 794
- economic models 789, 793, 794, 800–802, 804
- EGFR *see* epidermal growth factor receptor
- EHR *see* electronic health record
- EHRs
 - isolated 1421
 - monolithic 1408
 - multiple 1407
 - patient's 234
 - provider 1409
 - rearchitecting 1408
- electronic health record (EHR) 32, 204, 228, 230, 234, 252, 733, 1394, 1395, 1402, 1403, 1407, 1408, 1410, 1412–1415, 1421–1423, 1425, 1426, 1431
- electronic medical record (EMR) 209, 212, 213, 637, 768, 1340, 1341, 1346–1348, 1360, 1411
- electronic support systems 1440, 1446, 1453, 1455, 1456, 1458, 1459, 1462–1465
- EM *see* expectation-maximization
- EMA *see* European Medical Agency
- empirical Bayes estimates (EBEs) 1286, 1289, 1290
- EMR *see* electronic medical record
- EMs *see* extensive metabolizers
- EMs and PMs 423, 427, 430, 431, 443, 459, 463, 489
- epidermal growth factor receptor (EGFR) 17, 20, 91, 92, 116, 235, 612, 904, 958, 959
- European Medical Agency (EMA) 632, 675, 731, 915, 923, 995, 1187, 1188
- evaluation
 - biomarker 632, 654
 - clinical 64, 120
 - comprehensive 1456

- expert 763
- manual 761
- model-based 792
- new product 39
- patient 32
- scientific 649
- systemic 676
- toxicity 131
- website 1456
- events 99, 297, 653, 674, 907, 962, 1127, 1129, 1131, 1133, 1134, 1153, 1169, 1254, 1392
- atherothrombotic 1118
- biological 620
- cellular trafficking 132
- cerebrovascular 343
- chance 789
- clinical 861, 1126
- crossover 447, 448, 603
- fatal 1151
- hypoglycemic 401
- long-term 1141
- molecular 99
- nuclear 133
- rare 729, 1178
- recurrent 861, 1144, 1146
- thrombotic 1132
- tragic 4
- evidence-based medicine 82, 101, 342, 768, 913, 954, 960, 979, 997, 1424, 1445, 1466
- evolution 16, 109, 180, 183, 201, 442, 646, 686, 706, 716, 749, 758
- excretion 156, 467, 652, 687, 702, 749, 911, 1125, 1223, 1228
- biliary 697
- cellular 1304
- electrolyte 393
- fecal 471
- potassium 393
- renal 427, 466, 1309
- uric acid 393
- urinary sparteine 427
- expectation-maximization (EM) 328, 345, 347, 348, 430, 488, 863, 956
- experiments 153, 178, 184, 231, 258, 275, 465, 617, 663, 665, 674, 678, 1431, 1447
- clinical 293
- genetic 647
- inexpensive 258
- preclinical animal 101
- unique 665
- extensive metabolizers (EMs) 346–352, 396, 413, 414, 418, 422–424, 427, 428, 450–459, 461, 462, 464, 467, 469–475, 477–480, 486–490, 859–861, 863–867
- factors
 - adipocyte-derived 1193
 - bioactive 29
 - cellular 1136, 1143
 - clinical 962, 1135, 1142, 1144
 - critical 31, 222, 235, 1389, 1458
 - donor 1248
 - elongation 266, 274
 - environmental 194, 610, 620, 701, 821, 901, 961, 1176, 1228, 1255, 1337, 1353, 1460
 - epidermal growth 958
 - extrinsic 954
 - hemostatic 1137
 - human binding 711
 - inherited 1173
 - intrinsic 954
 - investigated 714
 - key 182, 698, 1173, 1445
 - limiting 704
 - lipid 1175
 - microenvironmental 1257
 - nonbiological 826

- nongenetic 388, 613, 1344, 1348, 1352, 1373, 1383
- nuclear 279, 1195
- organizational 1445
- paracrine 1256
- patient-related 1445
- predictive 20, 1355
- pro-inflammatory 1313
- provider-related 1445
- regulatory 1255
- socioeconomic 1259
- soluble 1255, 1257
- system-related 1445
- technical 192
- tumor necrosis 70
- vascular endothelial growth 1257
- false discovery rate (FDR) 260
- families 19, 167, 168, 375, 376, 706, 747, 923, 993, 1150, 1180, 1364, 1370
 - chemical 410
 - derivative 394
 - mammalian CYP2D 443
- family history 182, 226, 735, 1336, 1344, 1345, 1347, 1348, 1351, 1352, 1355, 1364, 1366, 1367, 1388, 1393, 1419
 - patient's 1389
- FDR *see* false discovery rate
- feces 392, 396, 402, 411, 412, 416, 465, 469, 472, 481, 486, 1204
- field
 - electric 28, 29
 - emerging 8, 59, 61, 221, 766, 919, 1262
 - magnetic 620
 - microarray 176
 - multidisciplinary 814, 817
 - scientific 293, 311
- first-order conditional estimation (FOCE) 1288
- flecainide 345, 347, 429, 468, 472, 473
- fluconazole 390, 392, 399, 475, 491
- fluids 110, 616, 696
 - biological 324
 - brain extracellular 110
- flunitrazepam 403, 413–416
- flunitrazepam metabolism 415, 416
- fluorouracil 44, 287
- fluoxetine 345–348, 353, 359, 403, 422, 423, 428, 454, 474, 490
- flurbiprofen 378, 385, 394, 398
- fluvastatin 399, 400
- fluvoxamine 348, 428, 455, 474, 475, 490, 990
- FOCE *see* first-order conditional estimation
- formal semantics 744, 754, 755, 757, 759, 761, 763, 768, 770
- framework 38, 230, 236, 662, 665, 685, 686, 688, 690, 692, 694, 696, 698, 716–718, 829, 830
 - basic 798
 - evaluative 782
 - extensible 242
 - general 322, 337
 - integrative 209
 - rank-by-feature 235
 - regulatory 673, 831
 - single 793
 - theoretical 784
- frequencies 300–302, 350, 351, 384, 386, 388, 396, 397, 408, 442, 445, 448, 449, 497, 600, 864, 978, 1309, 1310
 - allelic 388, 408
 - differential 350
 - distinct 301
 - exact 975
- function
 - abnormal 1206
 - administrative 1405
 - barrier 151
 - billing 1402

- biological 29, 183
- cellular 31, 61, 211, 259, 266, 901
- composite 698
- dynamic 1189
- efflux 176
- executive 359
- immune 1254
- linear 700
- lymphocyte 70
- mathematical 1277, 1284
- mitochondrial 133
- molecular 270, 305
- organ 767
- physiologic 1248
- physiological 749, 1204, 1222
- protective 1216
- psychomotor 416
- functional alleles 351, 447, 448, 451, 972, 974

- galantamine 464, 466, 467
- gaps 197, 200, 210, 222, 313, 670, 715, 1273, 1366, 1413, 1456
 - critical 250
 - current 223
 - potential 1409
- gastric acid secretion 962
- gastric acid suppression 422
- gastric parietal cells 418
- gastroesophageal reflux disease 419, 421, 962
- gastrointestinal fluids 143–145
- gastrointestinal membrane 146, 147
- gastrointestinal tract 142, 145–149, 164, 185, 426, 1174, 1213–1215
- GDP *see* gross domestic product
- gene duplication 349, 445, 448, 457
- gene expression 19, 60, 62, 69, 168, 171, 172, 175, 178, 179, 184, 225, 234, 1226, 1227, 1392, 1393
 - altered 131
 - differential 901
 - genome-scale 172
 - luciferase 100
 - pathogen 180
- gene expression profiles 24, 178, 181, 306, 617
- gene mutations 182
- gene ontology 207, 260, 286, 288, 296
- gene polymorphisms 344, 350, 1137
- genes
 - altered 206
 - annotating 307
 - apoptotic 135
 - circadian clock 1203
 - contiguous 1178
 - disease-associated 266
 - disease risk 672
 - effector 277, 280
 - functional 375, 1181
 - hub 271
 - human 172, 181, 238, 297, 618
 - human EGFR 119
 - human kinase 200
 - human protein-coding 1258
 - hybrid 446
 - immune-related 1313
 - important 175, 281
 - individual 185, 198, 634
 - key regulator 284
 - luciferase 624
 - multiple 803, 804, 1307, 1312, 1356, 1367, 1383
 - organism's 613
 - overexpressed 177
 - polymerase 64
 - protein biosynthesis 266
 - red cell function 1177
 - regulated 273, 280
 - ribosomal subunit 274

- signature 266, 270, 279–281
- signature union 271
- therapeutic 1225
- underconnected 272
- wild-type 1206
- gene signatures 131, 133, 135, 257, 259–261, 263–265, 267, 269, 271, 273, 275, 277, 281, 283
- gene therapy 72, 95, 131, 133, 817, 818, 1206, 1207, 1225, 1227, 1363
- genetic biomarkers 611, 612, 614, 630, 927
- genetic counseling 1347, 1358, 1361, 1368
- genetic counselors 833, 834, 1340, 1349, 1359, 1368
- genetic information 19, 182, 213, 342, 343, 495, 687, 730, 815, 845, 1340–1342, 1367, 1369, 1370
- Genetic Information
 - Nondiscrimination Act (GINA) 32, 213, 1369, 1370
- genetic mapping 203, 322, 326, 327, 339
- genetic markers 195, 200, 815, 910, 912, 1228, 1321
- genetic mutations 377, 430, 458, 494, 611, 627
- genetic polymorphisms 377, 626, 627, 712
- genetic research 814, 818, 823, 824, 828, 1338, 1339, 1354, 1356, 1365
 - cutting-edge 1361
 - high-throughput 213
- genetics
 - basic 1343, 1358
 - classical 1183
 - complex disease 671
 - de-identified 1341
 - enzyme 697
 - global core 1188
 - human 283
 - individual 1297
 - psychiatric 1366
 - using 874, 1337
- genetic tests 33, 625, 792, 793, 800, 818, 836, 1153, 1357, 1365, 1374
- genetic variants 356, 626, 627, 692, 698, 822, 874, 960, 961, 1348, 1349, 1354, 1355
 - associated 1354, 1355
 - common 1177
 - important 935
 - multiple 494, 1341, 1350
 - nominated 1354
 - personal 1343
 - rare 1316
 - reporting 1340
- genetic variations 180, 202, 203, 284, 312, 377, 385, 611, 1293, 1294, 1312, 1313, 1323–1325, 1336, 1337
- genome-wide 213
- human 202, 1339
- individual's 1337
- putative 662
- relevant 1376
- genomes 135, 180, 231, 232, 286, 313, 326, 610, 617, 652, 901, 1188, 1257, 1323, 1387
- human 198, 221, 617, 662, 1176, 1257, 1301, 1316, 1338
- patient's 1419
- whole 258
- genome-wide association (GWA) 337, 1294, 1316, 1320–1322
- genomic data 198, 207, 208, 901, 909, 911, 921, 1340, 1346, 1359
- genomic information 670, 675, 823, 906, 912, 930, 1336, 1337, 1346, 1358, 1360, 1362, 1372

- genomic medicine 34, 193, 800, 1340, 1372, 1373
- genomic research 814, 823, 831, 1337
- genotypes
 - diminished-function 354
 - double null 1307, 1308
 - heterozygotic 967
 - heterozygous 408
 - high-risk 790
 - marker 327
 - orphan 826
 - wild-type G/G 872
- GFR *see* glomerular filtration rate
- GINA *see* Genetic Information Nondiscrimination Act
- glimepiride 378, 400, 401, 988
- glomerular filtration rate (GFR) 702
- glucuronidation 391, 413, 423, 449, 459, 461, 465, 466, 469, 470, 485, 486, 627, 862, 1137, 1306
- glucuronides 392, 402, 459, 466, 467, 469, 475, 485–487, 489, 492
- glutathione 165, 167, 484, 1304
- glutathione S-transferase (GST) 908, 1307, 1308, 1324
- glyburide 378, 400
- glycoprotein 227, 1122, 1135
- glycosylphosphatidylinositol (GPI) 1200
- GPI *see* glycosylphosphatidylinositol
- GPI-anchored proteins 1201, 1222–1225, 1227
- GPI anchors 1222, 1223, 1227
- gross domestic product (GDP) 1335, 1336
- groups
 - academic 675
 - acetyl 1304
 - alcohol 466
 - benzimidazole 419, 420
 - chemical 1304
 - collaborative 237
 - collective 652
 - ether 469
 - heterogeneous 825
 - high-dose 872
 - low-dose 872
 - medium-dose 872
 - methoxy 465, 487
 - methylenedioxy 455
 - pharmacogenetic-guided 873
 - pyridine 419, 420
 - racial 858
 - therapeutic 1322
 - wild-type 401, 871
- growth
 - axonal 360
 - cellular 851
 - epidermal 116
 - exponential 232, 233
- GST *see* glutathione S-transferase
- GWA *see* genome-wide association
- GWA technique 1316, 1321, 1323–1325
- haloperidol 428, 459–461, 474, 491
- haplotypes 135, 355, 356, 360, 384, 385, 446, 604, 869, 870, 975, 976, 1316
- HCC *see* hepatocellular carcinoma
- HDL *see* high-density lipoprotein
- Health and Human Services (HHS) 632, 849, 1371
- health behaviors 1340, 1346, 1365, 1366
- health care
 - annual 222
 - cost-effective 1374
 - everyday 899, 913, 934
 - high-value 1382
 - long-term 1384

- health care budgets 779, 782, 786, 794
- health care costs 32, 95, 223, 728, 954, 1336, 1376
- health care delivery 32, 251, 837, 1375
- health care educators 907
- health care environments 899, 900, 906, 907, 916, 932
- health care practitioners 905, 906, 911, 921, 923, 928, 929
- health care professionals 730, 731, 733, 916, 924, 926, 1260, 1341, 1343, 1372, 1452
- health care providers 779, 781, 782, 801, 861, 909, 913, 920, 1336, 1343, 1345, 1346, 1348, 1356–1360, 1362, 1368, 1442, 1443
- health care resources 199, 781, 782, 797
- health care systems 41, 231, 715, 728, 779, 781, 782, 806, 828, 835, 867, 876, 913, 937, 1172, 1381–1383
- health conditions 1336, 1348, 1349, 1354, 1355, 1359, 1363
- health economics 782, 806
- health information exchanges (HIEs) 1386, 1403, 1407, 1408, 1431
- health information technology (HIT) 208, 1384, 1386
- health insurance 2, 213, 1369
- health promotion 1383, 1387, 1389, 1391, 1392, 1399, 1405, 1408, 1426
- science of 1382–1386, 1389, 1424, 1426, 1431
- health questionnaires 1342, 1344, 1353
- health-related quality of life (HRQoL) 781, 802
- health technology assessments (HTAs) 798, 801, 802
- healthy volunteers 358, 361, 389, 397, 398, 490, 491, 967
- hematopoietic stem cells (HSCs) 1249, 1250, 1253, 1255
- hepatic disorder NOS 749, 750
- hepatic enzymes 419, 700, 1141
- hepatic impairment 391, 846
- hepatitis 747–749, 758–760, 922, 1225, 1299
- chronic 227, 1307
- hepatitis cholestatic 749, 757, 758
- hepatitis cytolytic 747, 757, 758
- hepatocellular carcinoma (HCC) 227, 253
- hepatocytes 63, 164, 445, 483, 700, 701, 710, 1310, 1313
- hepatotoxicity 271, 424, 673, 674, 709, 710, 1295–1297, 1300–1304, 1306, 1307, 1311–1313, 1320, 1321
- diclofenac-induced 397
- drug 1298
- flucloxacillin 1321
- induced 1307
- lumiracoxib 1320
- nevirapine 1311
- paracetamol 1313
- transient 1295
- ximelagatran 1320, 1322
- HER2 *see* human epidermal growth factor receptor 2
- HER2-positive breast cancer 619, 853
- heterozygous EMs 410, 413, 414, 416, 420–422, 424, 455, 457
- HHS *see* Health and Human Services
- hierarchy 234, 304, 744, 747, 748, 750, 756, 757, 764, 1221
- HIEs *see* health information exchanges

- high-density lipoprotein (HDL) 66, 67
- high-dimensional data 221, 222, 318
- high-level group term (HLGT) 735, 736, 750
- high-level term (HLT) 735, 736, 741, 742, 750
- high-linear-energy-transfer (HLET) 112
- high-throughput technologies 19, 193, 200, 249, 829, 911
- HIT *see* health information technology
- HIT environment 1386, 1387, 1399, 1400, 1403, 1405, 1410, 1411, 1424, 1431
- HIV *see* human immunodeficiency virus
- HLA *see* human leukocyte antigen
- HLA alleles 978, 1320
- HLET *see* high-linear-energy-transfer
- HLGT *see* high-level group term
- HLTs *see* high-level term
- homozygous EMs 413, 414, 416, 420–424, 455, 473, 489
- HRQoL *see* health-related quality of life
- HSCs *see* hematopoietic stem cells
- HSS *see* Human Health Services
- HTAs *see* health technology assessments
- HUGO *see* Human Genome Organisation
- human epidermal growth factor receptor 2 (HER2) 17, 44, 618, 619, 785, 850, 851, 854, 855, 958, 1188, 1225, 1393
- Human Genome Organisation (HUGO) 162
- Human Health Services (HSS) 32
- human immunodeficiency virus (HIV) 23, 70, 71, 166, 416, 611, 624, 709, 846
- human leukocyte antigen (HLA) 611, 847, 878, 904, 955, 1313, 1314
- human liver 377, 425, 460, 484, 626, 688
- human liver microsomes 396, 397, 474, 475
- hydroxylated metabolites 387, 391, 399, 428, 452, 475, 492, 493
- IAMs *see* immobilized artificial membranes
- IAP *see* intestinal alkaline phosphatase
- ibuprofen 378, 393, 397, 398, 1145, 1302
- ICER *see* incremental cost-effectiveness ratio
- ICH *see* International Conference on Harmonisation
- ICOB *see* Informed Cohort Oversight Board
- ICSRs *see* Individual Case Safety Reports
- imaging 13, 19, 30, 100, 341, 1411
- antisense 86
- bioluminescence 100
- brain tumor 86
- capillary 97
- cellular 1262
- cross-sectional 81
- diffusion-weighted 99
- fluorescence 100
- functional 88, 91
- functional radionuclide 85, 86, 95, 101
- high-resolution 100
- tumor metabolic 98

- imipramine 403, 423, 428, 443, 444, 449, 451, 955
- immobilized artificial membranes (IAMs) 152, 154
- immune cells 70, 1175, 1193, 1194
- immune responses 66, 69, 977, 1226, 1253, 1296, 1313, 1314, 1325
- immune system 59, 61, 63, 212, 627, 1192, 1193, 1253, 1254, 1293, 1313, 1325
- IMs *see* intermediate metabolizers
- incremental cost-effectiveness ratio (ICER) 781, 786, 787, 796, 797, 799
- Individual Case Safety Reports (ICSRs) 733
- indomethacin 176, 177, 294, 378, 396–398, 1302
- inflammation 69, 71, 97, 211, 752, 753, 1195, 1196, 1252, 1257
 - acute 752, 753
 - cellular 1195
 - concomitant 1198
 - hypothalamic 1196
 - induced 284
 - lymphocyte-associated 1193
 - neuronal 1196
 - obesity-associated 1192, 1194
 - suppressing 1252
 - systemic 1192
- inflammatory bowel disease 626, 1252
- information component 754, 756, 760–762
- information extraction 293, 294, 297, 298
- information retrieval 214, 294, 298
- information systems
 - clinical 207, 208, 733
 - electronic 199
- information technology 729, 1402, 1405, 1439, 1460
- Informed Cohort Oversight Board (ICOB) 1342, 1354, 1355
- infrastructure 32, 222, 900, 924, 926, 936, 937, 1372, 1400, 1401, 1405, 1406, 1411, 1453, 1460
 - clinical 902
 - information-based 902, 929
 - multidisciplinary 927, 928, 933
 - scientific 231
 - secure hardware 1370
 - technological 895
- inhibitors 40, 165, 176, 345–348, 378, 390, 392, 456, 463, 471, 710, 936
 - angiotensin II 386
 - cyclooxygenase-1 1118
 - disappeared using P-gp 164
 - moderate reuptake 453
 - molecular targeted 8
 - noradrenaline reuptake 456
 - opioid receptor 490
 - phosphodiesterase III 1149
 - serotonin reuptake 211, 343, 403, 422, 454, 1374
 - soya bean trypsin 1215
 - suicide 411
 - thrombin 1320
 - weak reuptake 453
- injury 1256, 1257, 1312, 1315, 1322
 - acid-related hepatocyte 1311
 - hepatocellular 1322
 - permanent 966
- INR *see* international normalized ratio
- insulin 110, 402, 1143, 1144, 1172, 1173, 1182, 1189, 1191, 1215, 1216, 1222
 - circulating 1196
 - delivered 1214
 - secreted 1173

- insulin receptor substrate (IRS) 1143
- insulin resistance 1144, 1173, 1176, 1177, 1181, 1184, 1189, 1192–1195, 1198, 1203, 1204
- insulin secretion 1176, 1189, 1190
 - glucose-induced 1173
 - impaired 1173
- integration 17, 22, 198, 199, 205–208, 214, 646, 658, 679, 680, 926, 927, 932, 997, 1375, 1424, 1425, 1462
 - clinical 912, 1358
 - device 9
 - documented 679
 - gradual 910
 - large-scale 206
 - mathematical 931
 - microfluidics 22
 - numerical 706
 - practical 916, 930
 - slow 996
 - synchronized 2
 - systematic 715
- interfaces 224, 634, 909, 910, 919, 933, 1220
 - clinic-research 235
 - easy-to-use 236
 - graphical user 294
 - interactive 241
 - patient-clinic 235
- interindividual variability 389, 417, 424, 496, 497, 863, 894, 901, 959, 1271, 1272, 1280–1282, 1284, 1286–1289
- interindividual variations 130, 430, 494, 497, 611, 1300, 1307
- intermediate metabolizers (IMs) 349, 350, 445, 447, 452, 464, 473, 477, 478, 489, 857–861, 958, 968, 972, 1141
- International Conference on Harmonisation (ICH) 733, 734, 824
- international normalized ratio (INR) 387, 868, 870–872, 966
- internet 294, 299, 681–683, 820, 832, 834, 1342, 1402, 1407
- interoperability 208, 912, 1403, 1412, 1413, 1425
- interplay 687, 702, 894, 901, 1228, 1383, 1389
- intestinal alkaline phosphatase (IAP) 133
- intestinal epithelial cells 1213
- intestinal membrane 151, 156, 161, 168
- intestinal mucosa 148–150, 376
- intestine 151, 164, 166, 168, 426, 427, 688, 693, 702, 966, 970, 975, 1214
 - human 151, 155, 426
 - upper 1205
- intravenous injection 70, 89
- intrinsic clearance 383, 387, 447, 474, 700, 711
- IRS *see* insulin receptor substrate
- ischemic events 411, 1126, 1134, 1149, 1151, 1152, 1169
- Japanese patients 351, 357, 420, 421, 449, 458, 461, 473, 493
- Japanese population 384, 408
 - healthy 494
- Java Messaging Service (JMS) 242
- JMS *see* Java Messaging Service
- KD *see* knowledge discovery
- ketobemidone 402
- key elements 196, 230, 236, 645, 649, 686, 1346, 1347, 1349, 1351, 1353, 1355, 1357, 1359, 1361

- Kirsten *ras* gene (*KRAS* gene) 612, 1374
- knowledge
- biological 924, 1275
 - complex 768
 - evidence-based 1384
 - expert 291, 729
 - external 296
 - extract 250, 771
 - inadequate 1358
 - mechanistic 669
 - molecular 908
 - multiple 205
 - pharmaceutical 293
 - pharmacogenomic 731, 768, 769
 - pharmacology 926
 - physiological 707
 - putative 728
- knowledge-based approaches 286, 287, 729, 731, 739, 740, 755, 765, 767–769, 1209
- knowledge discovery (KD) 60, 197, 198, 201, 204–206, 209–211, 214, 294, 770
- knowledge domains 197, 198, 200, 205, 210
- knowledge representation 199, 208, 211, 212, 736
- KRAS* gene *see* Kirsten *ras* gene
- laboratory 38, 173, 197, 205, 206, 208, 248, 740, 800, 832, 997, 1119, 1126, 1290, 1402, 1403
- abnormal 758
 - analytical 1290
 - clinical 631, 917, 978
 - clinical-diagnostic 927
 - dedicated 1126
 - genomic-related research 910
 - pharmaceutical 732
 - specialized 1123, 1124
 - testing 816
- language 35, 359, 744, 757
- extensible markup 298
 - natural 292, 299, 304, 311
- lansoprazole 403, 418–421, 963, 964
- LDA *see* linear discriminant analysis
- LDL *see* low-density lipoprotein
- LEC *see* lowest effective concentration
- light transmission aggregometry (LTA) 858, 1119, 1123, 1127, 1128, 1133, 1148
- likelihood ratio (LR) 329, 702
- linear discriminant analysis (LDA) 308, 627
- low-density lipoprotein (LDL) 66, 110, 400
- lowest effective concentration (LEC) 713
- LR *see* likelihood ratio
- LTA *see* light transmission aggregometry
- lymphoma 90, 91, 1416
- lymphosarcoma 4
- macrophages 10, 63, 70, 167, 1192, 1194, 1195, 1217
- Madin–Darby canine kidney (MDCK) 152, 154
- magnetic resonance imaging (MRI) 15, 16, 81, 82, 84, 85, 98, 99, 101, 225, 1189, 1393
- magnetic resonance spectroscopy (MRS) 82, 98, 1189, 1199
- major depressive disorder (MDD) 342, 353, 357, 359, 360, 362
- major histocompatibility complex (MHC) 977, 1252, 1314
- MALDI *see* matrix-assisted laser desorption ionization
- Mallory–Weiss syndrome 752, 753
- mammalian cells 100, 167, 1181

- management
 - business process 230
 - cancer patient 20
 - clinical 101, 784, 802, 1173
 - hospital 1461
 - patient 95
 - personalized 1336
- mapping
 - platelet 1128
 - polyadenylation site 368
 - semantic 208
- maprotiline 428, 449, 452, 453
- MAQC *see* MicroArray Quality Control
- masses 2, 8, 29, 93, 96, 225
 - abdominal 93
 - fetal 1183
 - inner cell 1249, 1256, 1261
 - molecular 641
 - nonpalpable 96
 - β -cell 1173, 1175
- mass spectrometry (MS) 24, 195, 618
- mathematical models 17, 156, 703, 927
 - advanced 260
 - parametric 1274
- matrix-assisted laser desorption ionization (MALDI) 25, 618
- matter 40, 182, 192, 752, 914
 - complex 701
 - delicate 137
 - white 114
- MCH *see* melanin-concentrating hormone
- MDCK *see* Madin–Darby canine kidney
- MDD *see* major depressive disorder
- mean fluorescence intensity (MFI) 1124
- mechanisms
 - biological 245, 274
 - carrier-mediated transport 110
 - cellular 61
 - complex 135, 180, 1190
 - detoxifying 1307
 - direct 1151
 - fundamental 178
 - genetic susceptibility 373
 - immune-related 1323
 - inclusion/exclusion 750
 - metabolic 336
 - molecular 14, 86, 894, 900, 1190, 1199
 - multiple 1144
 - multiscale 137
 - natural cellular 60
 - passive diffusion 148, 149
 - passive transcellular 161
 - pathogenic 1214
 - privacy protection 824
 - putative 1304
 - regulatory 1257
 - regulatory approval 832
 - retrieval 238
 - systemic 211
 - therapeutic 5, 36
- medical care 342, 823, 1336, 1337, 1354, 1369, 1373, 1389, 1440, 1442
- medical conditions 646, 742, 744, 765, 1446, 1454
- medical decisions 820, 836
- medical devices 35, 37, 608, 630, 632, 1387
- medical genomics 256
- medical history 182, 826, 997, 1344, 1347, 1364, 1388, 1389
- medical imaging 1189, 1407, 1420
- medical informatics 292, 306, 776
- medical practice 193, 769, 814, 825, 826, 954, 1443, 1444
- medical professionals 1348, 1359, 1361, 1372, 1375
- medical research 823, 907, 937, 1335, 1338, 1339
- medical specialties 916, 930, 1456–1458

- medical treatments 32, 323, 608, 1248, 1337, 1350, 1387, 1426, 1443
- medications 41, 341, 344–348, 350, 363, 425, 631, 715, 767, 769, 1294–1296, 1308
 - antidepressive 371
 - antiplatelet 1117
 - concomitant 967
 - concurrent 691, 874
 - expensive 636
 - generic prescription 1296
 - multiple 1455
 - over-the-counter 343
 - psychotropic 344, 352, 934
- medicine
 - antimalarial 777
 - clinical 2, 8, 200, 1464
 - cost-effective 646
 - defensive 1382
 - intuitive 1390, 1391, 1424
 - modern 4, 1464
 - trial and error 1391, 1422–1424, 1431
- melanin-concentrating hormone (MCH) 1191
- melanocyte-stimulating hormone 1191
- membranes 14, 61, 65, 68, 132, 150, 151, 157, 162, 176, 692, 698, 1218
 - apical 164
 - apical canalicular 1310
 - basal 110
 - bilayer 117, 118
 - biological 164
 - immobilized artificial 152
 - lipid 149, 150
 - liposomal 114
 - luminal 164
 - natural 1223
 - nuclear 133
 - nylon 172, 173
 - phospholipid 111
 - subcellular 1217
- mephenytoin 413, 458, 898
- mesenchymal stem cells (MSCs) 27, 28, 1249–1252, 1254–1257, 1259–1261, 1263
- metabolic activity 398, 1142, 1302
- metabolic clearance 164, 427, 700, 866
 - hepatic 713
 - intrinsic 701
 - partial 457, 474
- metabolic diseases 1171, 1172, 1174, 1176, 1178, 1180–1182, 1184, 1186, 1188, 1190, 1194, 1196–1198, 1206, 1212–1214, 1226–1228
- metabolic disturbances 1192
- metabolic drug clearance 717
- metabolic dysfunction 1192, 1197
 - obesity-associated 1194
 - pregnancy maternal 1176
- metabolic elimination 390, 703
- metabolic enzymes 265, 270, 703
- metabolic pathways 350, 423, 431, 449, 457, 465, 483, 491, 620, 700, 1300
- metabolic polymorphism 343, 345, 347, 349, 351
- metabolic ratio 427, 472, 955, 957, 995
 - higher median 449
 - urinary 394, 474
- metabolic syndrome 1195, 1197, 1203, 1229, 1299
- metabolism
 - abnormal 729
 - amino acid 85
 - bilirubin 975
 - carbohydrate 1203
 - diclofenac 397
 - extensive 460, 471
 - glucose 85, 358, 467, 1203
 - gut wall 698, 717

- housekeeping 376
- human adult 1175
- impaired 387, 420
- increased 865, 1141
- lipid 1203
- nitric oxide 641
- one-carbon cycle 373
- oxidative 376, 383, 424, 493
- oxidative carbon 475
- polymorphic 462
- poor 395, 625
- preferential 471
- protein 621
- reduced 1141
- regional brain 371
- regioselective 387
- renal 703
- saturable 451
- secondary 459
- sequential 484
- slow 714
- tumor 82, 90
- xenobiotic 718
- metabolites
 - 10-hydroxy 450
 - 10-hydroxylated 387, 452
 - 2-chloroticlopidine 411
 - 4-hydroxylated 424
 - 7-hydroxylated 387
 - 9-hydroxy 460
 - active thiol 856
 - acyl glucuronide 1306
 - antiestrogenic 486
 - carboxyl 392
 - catechol 455, 483
 - conjugated 486
 - O*-demethyl 471
 - demethylated 453, 457
 - dihydroxylated 391
 - droxylated 414
 - estrogenic 485
 - hepatotoxic 1305
 - hydroxy 419
 - inactive 856, 1140
 - keto 392
 - methylhydroxylated 393
 - minor 481, 484
 - primary 392, 459, 488
 - primary urinary 389
 - quinone methide 484
 - reactive 1308, 1310, 1313
 - sulfone 418, 419
 - venlafaxine's 344
 - water-soluble 641
- metabolizers 344, 351, 625, 1151
 - atypical 344, 363
 - fast 496
 - intermediate 349, 350, 430, 857, 956, 1141
 - rapid 963
- metabolomics 2, 19, 221, 225, 234, 239, 248, 250, 620, 831, 902, 1186, 1198, 1326
- methods
 - algorithmic 311
 - automated 737, 739
 - computerized 912
 - data normalization 206
 - data visualization 234
 - dynamic contrast 108
 - elicitation 794
 - experimental 203
 - gene set discovery 215
 - hydrodynamic 63
 - independent 1274
 - indirect 165
 - integrative 207, 209
 - interpolation 1276
 - knowledge-based 745, 768, 771
 - least squares 1277
 - machine-learning 308
 - major technical 204
 - mathematical aggregation 794
 - microarray 173
 - microarray hybridization 495
 - model-independent 1274
 - modern machine-learning 308
 - modern synthesis 1208

- network-based 282
- noninvasive 627, 1214
- oil-in-water emulsion 1221
- optimal 1127
- osmotic 111
- pharmacodynamic 718
- planar 85
- radionuclide 93
- semiautomatic 294, 750, 764
- silico 156, 160, 161, 911
- supported ontology 207
- transfection 61, 69
- unsupervised 317
- metoprolol 428, 468, 470, 476–478, 966
- MFI *see* mean fluorescence intensity
- MGED *see* microarray gene expression data
- MHC *see* major histocompatibility complex
- MI *see* myocardial infarction
- mianserin 428, 458
- mice 64, 70, 71, 115, 116, 118, 119, 165, 271, 391, 426, 485, 1198, 1200
 - cirrhotic 68
 - double-knockout 1313
 - humanized 70, 427
 - knockout 426
 - murine 115
 - normal 1193
 - transgenic 426, 427
 - tumor-bearing 69, 116, 118, 119
- micelles 11, 12, 1216, 1217, 1219
- microarray data 183–185, 206, 230, 231, 250, 254
- microarray gene expression data (MGED) 231, 635
- MicroArray Quality Control (MAQC) 630, 643
- microarrays 19, 133, 168, 169, 171–184, 306, 617
- microsomes 493, 700
 - human 465
 - placental 400
- microvesicles 1198, 1200
- mitochondria 133, 1195, 1199, 1201, 1202
- moclobemide 403, 423, 453
- modalities 84, 98, 99, 101, 1204, 1247
 - radionuclide 85, 87
 - therapeutic 59, 62
- model, mouse 1193, 1259
- modeling 201, 210, 214, 248, 303, 686, 687, 716, 748, 763, 799
 - abstraction 210
 - computer 151
 - economic 794
 - equation-based 211
 - mathematical 13, 324
 - mechanistic 687
 - molecular 1212
 - nonclinical 37
 - nonlinear mixed effects 1280
 - ontological 749, 750
 - parsimonious 322
 - predictive 1394, 1395, 1416, 1418, 1425
 - statistical 260
- model parameters 332, 333, 793, 795, 805, 1275–1277, 1279, 1283, 1286, 1287
- model performance 260, 264, 277, 278
- models
 - accurate 156
 - analytic 789
 - biosimulation 209
 - classic 1356
 - clinical decision support 205
 - clinical PGx 931
 - complex 704, 794
 - conceptual 1417, 1419
 - cost-efficient 205
 - dynamic 338

- efficient 1339
- empirical 1276
- experimental 1183, 1205
- exponential 1284
- frame-based 746
- hub-and-spoke 1360
- human xenograft 65
- hypothetical 1227
- integrated 254
- linear regression 874
- multigenic 1350
- murine 1252
- nested 748
- onesize-fits-all 1336
- oral cancer 118
- pain threshold 488
- parametric 1275
- patient-centric 1336
- permeability-limited 704, 705
- pharmacogenetic 961, 995
- pipeline 496
- quantitative 284, 916
- rat tumorigenesis 851
- semi-mechanistic 688, 719
- silico 161, 234, 695
- silico permeability 157
- statistical 259, 273, 274, 634
- vector space 298, 299
- xenograft 68
- model structure 325, 791, 794, 795, 798
- moieties 118, 454, 705
 - calcium-binding 56
 - chelating 101
 - electrophilic 1307
 - indole 399
 - multiple chemical 706
 - protein 1223
 - sugar 1220
 - tetrahydropyridine 411
 - tetrazole 391
 - therapeutic 141
 - tumor-targeting 113
- molecular biomarkers 609–611, 613, 615, 617, 619, 621, 628–637, 1393
- molecular clock 1203, 1204
- molecular diagnostics 765, 901, 906, 910, 927, 1248, 1455
- molecular imaging 16, 17, 42, 82, 83, 87, 95, 101, 1392, 1395
- molecular level 31, 97, 131, 195, 201, 203, 766, 894, 910, 923, 1184, 1212, 1396, 1399
- molecular markers 32, 239, 336
- molecular pathways 16, 248, 259, 766, 1175, 1393, 1396
- molecular profiles 8, 32, 175, 243
- molecular targets 17, 18, 1175
- molecular weight 25, 60, 63, 110, 150, 377, 1226
- morphine 425, 487, 488, 862, 863, 865–867, 981
 - active form 487
- morphine 3-ethereal sulfate 487
- MRI *see* magnetic resonance imaging
- MRS *see* magnetic resonance spectroscopy
- MS *see* mass spectrometry
- MSCs *see* mesenchymal stem cells
- MSH *see* melanocyte-stimulating hormone
- MSVs *see* multistage silicon vectors
- multistage silicon vectors (MSVs) 14, 44
- muscle 27, 28, 621, 703, 1189, 1198, 1207, 1224, 1225
 - impaired 1173
 - leg 1200
 - skeletal 1192, 1200
- mutant alleles 387, 442, 443, 494
- mutations 19, 41, 42, 130, 382, 611, 612, 622, 623, 964, 1178–1181, 1311
 - cancer-causing 33
 - germ-line 613

- inherited 1180
- isolated 1300
- nonsynonymous 444, 1311
- obesity-related 1180
- somatic 613, 958
- splice-site 612
- myocardial infarction
 - acute 959,
 - nonfatal 959
- myocardial infarction (MI) 203, 411, 856, 1131, 1137

- named entity recognition (NER) 212
- nanocarriers 64, 76
- nanodiagnosics 19–22, 917
- nanomaterials 30, 34, 36, 37, 133, 917, 1222, 1223
- nanomedicine 2, 8–11, 30, 34, 35, 37–39, 136, 894, 895, 918, 937
- personalized 134, 919, 937
- nanoparticles 10, 11, 13, 17, 18, 21, 23, 28, 29, 36–39, 63, 65, 71, 72
 - active 21
 - injected 10
 - multiple 13
 - second-stage 13
 - therapeutic 131
- nanoporous silica chips (NSCs) 25
- nanovectors 9, 12, 13, 15, 16, 48
- National Institutes of Health (NIH) 38, 239, 304, 609, 637, 1338, 1346, 1350, 1362, 1367, 1371
- natural killer (NK) 12, 1193
- natural language processing (NLP) 212, 309, 766, 1416
- nausea 457, 490, 742, 984, 986, 991, 998
 - chemotherapy-induced 479
- NBD *see* nucleoside-binding domains
- NDA *see* new drug application
- N*-dealkylation 410, 461, 462, 465, 470, 475, 477, 479
- N*-demethylation 402, 413–415, 422, 429, 430, 449, 450, 454, 456, 458, 466, 471, 482, 484, 490, 492
- N*-desmethylclobazam 415
- N*-desmethylgalantamine 466, 467
- N*-desmethyltamoxifen 481, 482, 484
- N*-desmethylvenlafaxine 456, 457
- NEC qualifiers *see* not-elsewhere-classified qualifiers
- negative predictive value (NPV) 673, 674
- nelfinavir 403, 416, 417
- neoadjuvant chemotherapy 94, 853
- NER *see* named entity recognition
- networks
 - artificial neural 211
 - biological 260, 909
 - complex 110
 - external 1211
 - functional 204, 359
 - growing 311
 - interactive 200
 - intertwined 1190
 - molecular 901, 927
 - multicenter 1325
 - private 1407
 - semantic 751, 772
 - signature 288
 - storage array 1370
 - web-enabled 226
- neurons 426, 1190, 1249
 - ectodermal 1249
- neurotransmitter systems 352, 353, 355
- neutron 109, 112, 124–126
 - low-energy 111

- slow-moving epidermal 113
- thermal 119
- neutron irradiation 116, 118
- neutropenia 627, 805, 904, 966
 - azathioprine-induced 806
 - septic 805
- new drug application (NDA) 663
- new drugs 42, 178, 183, 656, 715, 736, 825, 827, 837, 924, 996, 998
- new knowledge 234, 740, 833, 924, 1395, 1419
- new pharmacogenomic tests 819, 830, 832
- new technologies 20, 38, 45, 175, 184, 221, 258, 610, 646, 655, 794, 803, 1397, 1399
- next-generation sequencing 193, 232, 636, 1262
- nicergoline 467
- NIH *see* National Institutes of Health
- NK *see* natural killer
- NLP *see* natural language processing
- NMR *see* nuclear magnetic resonance
- NNRTI *see* non-nucleoside reverse transcriptase inhibitor
- nonfunctional alleles 351, 960, 961
- nonlinear regression 1277, 1279, 1280, 1286
- non-nucleoside reverse transcriptase inhibitor (NNRTI) 711, 725
- non-small-cell lung cancer (NSCLC) 41, 92
- non-steroidal anti-inflammatory drugs (NSAIDs) 378, 386, 393–398, 904, 981, 986, 994, 1137, 1145, 1295
- nonviral vectors 1207, 1226
- noradrenaline 452, 957, 958
- norketobemidone 402
- normalized ratio 388
 - international 387, 868, 966
- nortriptyline 403, 428, 449–451, 714, 897, 956
- NOS qualified *see*
 - not-otherwise-specified qualifiers
- not-elsewhere-classified qualifiers (NEC qualifiers) 750
- not-otherwise-specified qualifiers (NOS) 750, 751
- Noxidation 410, 424, 465, 466, 474, 475, 493
- N*-oxide 424, 427, 484, 485, 492
- NPV *see* negative predictive value
- NSAIDs *see* non-steroidal anti-inflammatory drugs
- NSCLC *see* non-small-cell lung cancer
- NSCs *see* nanoporous silica chips
- nuclear magnetic resonance (NMR) 195, 485, 620
- nucleic acids 19, 22, 67, 167, 611, 766, 1172, 1209, 1214, 1216, 1224, 1226, 1227
- nucleoside-binding domains (NBD) 163
- nucleotides 60, 135, 353, 383, 975, 1214
- null alleles 349, 383, 384, 407, 494, 968, 976, 1307
- null genotypes 1307
- obesity
 - abdominal 1184
 - basic 1190
 - childhood 1191
 - extreme 1178, 1204
 - maternal 1183
 - morbid 1205
 - peripheral 1184, 1197
 - severe 1194

- obesity epidemic 1171
- obesity surgery (OS) 262, 263, 1204, 1205
- objective function 1277–1279, 1285, 1287
 - modified 1286
 - unweighted 1278
- OCP *see* Office of Combination Products
- ODEs
 - first-order 325
 - spline-enhanced 325
- ODEs *see* ordinary differential equations
- Office of Combination Products (OCP) 37
- olanzapine 348, 355, 356, 362, 428, 460, 464, 982, 985, 987
- oligonucleotides 21, 173
- omeprazole 348, 403, 410, 418, 420, 421, 475, 963, 964, 1145
- OMIM *see* Online Mendelian Inheritance in Man
- Online Mendelian Inheritance in Man (OMIM) 202, 203, 239, 298
- ontologies 231, 260, 261, 270–272, 275, 278, 282, 304, 731, 744–747, 749, 750, 753–756, 758–760, 763–766, 768, 773–775
 - comprehensive 231
 - formal 749, 754, 757, 758, 760, 763
 - functional 260, 270, 276, 282
 - graphical 282
 - knowledge based 282
 - manual 745
 - popular 304
 - reusable 776
 - synonym-based 752
 - terminological 757, 758
- oral administration 160, 161, 389, 392, 411, 456, 472, 474, 475, 477, 485, 488
- oral clearance 394, 430, 431, 453, 457, 464, 472, 473, 476, 490, 492, 493
- oral drug absorption 185, 689, 697, 717
- ordinary differential equations (ODEs) 323–325, 327, 337, 703, 706, 723
- organism 19, 171, 258, 613, 894, 910, 913, 924
- organs 63, 69, 325, 688, 693, 700, 703, 830, 910, 917, 921, 1198, 1249, 1250
 - endocrine 1175
 - major 914
 - steroidogenic 67
- OS *see* obesity surgery
- outcomes
 - clinical improvement 919
 - clinical thrombotic 1141
 - drug-delivery 316
 - efficient therapy 933
 - fatal 713
 - injurious 1313
 - ischemic 1126
 - misinterpreted 61
 - neurological 216
 - optimal medical 1185
 - proxy 805
 - radiographic 216
 - systemic 216
 - therapeutic 200, 201, 1262
 - variable 1248
- oxidation 100, 378, 390–392, 410, 411, 471, 474, 478, 483, 490, 492, 1140, 1305
 - catalyzed 411
 - mitochondrial 1200
- PAD *see* peripheral arterial disease

- PAMPAs *see* parallel artificial membrane permeation assays
- pantoprazole 403, 418–420, 964, 1145
- paracetamol 176–178, 865, 1295
- parallel artificial membrane permeation assays (PAMPAs) 152
- parameter estimation (PE) 707
- parameters
 - adverse event 802
 - biochemical liver 1304
 - biological 156
 - clinical 227, 247
 - covariance-structuring 331
 - disease-free survival 245
 - kinetic 397
 - non-clinical 633
 - nonoptimized 1259
 - organ 705
 - patient's 1288
 - physiological 707
- paroxetine 346, 347, 355, 422, 428, 454, 455, 463, 474, 477, 490
- PAT *see* process analytical technology
- pathogenesis 201, 852, 914, 1134, 1181, 1184, 1186, 1189, 1200, 1213, 1222, 1325
 - dengue 70
 - human cancer 878
- pathways 44, 100, 258, 261, 272, 273, 281–284, 288, 477, 478, 633, 634, 1119, 1124, 1125, 1144, 1180
 - activated 44
 - biochemical 322, 323, 337
 - branch 789
 - cancer-related 271
 - canonical 274
 - carcinogenesis 271
 - caveolae-mediated 133
 - cell cycle 271
 - complex 1174
 - detoxification 485
 - drug elimination 689
 - drug mechanism 284
 - dysregulated 1174
 - host defense 180
 - lipopolysaccharide synthesis 1204
 - melatonin 1177
 - multiple 1200
 - oxidative stress 271
 - passive transcellular 157
 - pathological 14, 284
 - pathophysiological 203
 - pharmacological 927
 - platelet-signaling 1152
 - platelet-signaling 1150
 - renal 394
 - salvage 167
 - virulence 180
- patient cohorts 237, 238, 243–245, 247, 634, 1179
- patient data 2, 8, 230, 1297, 1418, 1421, 1422, 1424, 1441, 1442
- patient information 2, 1390, 1391, 1399, 1406, 1415, 1419, 1423, 1426, 1442
- patient outcomes 180, 248, 801–805, 1298, 1440, 1443, 1446, 1453, 1454, 1458, 1459, 1463, 1464
- patient populations 2, 42, 45, 197, 687, 691, 781–784, 786, 795, 802, 804, 805, 958, 1260, 1261, 1385, 1414, 1415
 - large 1418
 - prespecified 781
 - selected 954, 997
 - virtual 715
- patients
 - adult 464
 - already-sick 818
 - anxious 350
 - aspirin-treated 1137

- black 848
- cardiac 165
- clozapine-treated 355, 1016, 1017
- depressive 453
- diabetic 401, 1183
- dual resistance 1132
- elderly 342, 457, 463, 868
- elderly Dutch 459
- epileptic 382, 415
- faroese 489
- geriatric 359, 362
- heterozygous 459
- hospitalized 921, 922
- impaired 694
- infected 1192
- malaria 526
- male 473
- medication-naive 359
- naive 622
- node-positive 851
- nongeriatric 359
- nonmetastatic 248
- nonobese 1205
- olanzapine-treated 357, 369
- orphan drugs 819
- pediatric 424
- polypharmacy 1146
- psychiatric 464
- African Caribbean 357
- real-world 1409
- refractory 355
- risk-stratifying 730
- rural 45
- treatment-refractory 362
- virtual 711, 1416
- warfarin-resistant 389
- warfarin-treated 638
- white 848
- patient subgroups 195, 196, 200, 691, 1247
- PCA *see* principal component analysis
- PCI *see* percutaneous coronary intervention
- PCPs *see* primary care physicians
- PCR *see* polymerase chain reaction
- PDT *see* personalized drug therapy
- PE *see* parameter estimation
- PEG
 - synthetic hydrophilic polymer 1218
 - transferin-coupled 67
- PEG *see* polyethylene glycol
- peptides 13, 22, 24, 67, 97, 110, 116, 227, 355, 977
 - agouti-related 1191
 - cell-penetrating 61
 - histidine-lysine 68
 - polylysine 66
 - processed foreign 1314
- percutaneous coronary
 - intervention (PCI) 859, 860, 960, 1118, 1128, 1131, 1134, 1141, 1142, 1147
- peripheral arterial disease (PAD) 856
- permeability 112, 151, 152, 155, 157, 159, 161, 164, 165, 689, 692, 704, 711, 1216
 - calculated 157
 - compound's 156
 - drug/formulation 168
 - drug's 704
 - increased 65, 110
 - poor 157
- personal health records 734, 1402, 1406–1408, 1413
- personalized drug therapy (PDT) 931, 933
- personalized health care (PHC) 32, 1184, 1381, 1383, 1385–1387, 1389–1394, 1397, 1399, 1400, 1403–1405, 1414–1416, 1422–1426, 1431, 1432

- personalized prognosis 1171, 1172, 1174, 1176, 1178, 1180, 1182, 1184, 1186, 1188, 1190, 1192, 1194, 1228
- personalized stem cell therapy 1252, 1254, 1255, 1258, 1259, 1261, 1262
- personalized therapies 12, 18, 131, 184, 214, 636, 1189, 1206, 1207, 1255, 1465
- PET *see* positron emission tomography
- PFA *see* platelet function analyzer
- pharmaceutical companies 42, 609, 611, 646, 656, 675, 680, 731, 732, 739, 820, 825, 826, 833, 834, 837, 1188
- pharmaceutical industry 2, 191, 192, 608, 646, 658, 670, 675, 680, 683, 686, 735, 739, 816
- pharmacogenomic interventions 781–785, 788, 791, 794, 795, 798, 800–806
- pharmacokinetic parameters 325, 330, 687, 710, 712, 1272, 1274, 1276, 1277, 1279, 1280, 1284, 1286
- PHC *see* personalized health care
- phenotypes
 - acetylator 1305
 - altered 901
 - common obesity 1177
 - complex 260, 336, 1178
 - complex human 283
 - differential drug response 312, 911
 - expected cancer 272
 - genotype-derived 477, 478
 - health-related 1350
 - human 298
 - individual 179
 - individual's tumor 101
 - metabolizer 344, 351
 - obesity-related 1177, 1181
 - pathological 1182
 - poor metabolic 605
 - sporadic 1178
 - syndromic 1178
 - systemic 1182
 - ultrarapid 407
 - virtual 642
- PHRs *see* personal health records
- piroxicam 378, 383, 395–398
- plasma 24, 25, 160, 238, 324, 325, 392, 411, 413, 414, 461, 462, 482, 484, 492, 699, 703
 - complex body fluids 24
 - platelet-rich 1119, 1127
 - steady-state 472
- plasma concentrations 165, 327, 343, 348, 389, 398, 414, 450, 457, 464, 465, 471, 490
- plasma levels 344, 347, 417, 461, 467, 470, 472, 478, 481, 491, 956, 1198
- plasma proteins 692–694, 698, 700, 702
- platelet aggregation 410, 859–861, 1125
 - maximal 858, 1151
- platelet function 857, 1119, 1121, 1123–1127, 1129, 1131, 1133, 1134, 1137, 1142, 1145, 1146, 1153
- platelet function analyzer (PFA) 1125
- platelet function tests 1119, 1128, 1132
- platelet inhibition 1124, 1134, 1146–1150
 - clopidogrel-mediated 1137
 - enhanced 1149
 - increased 1147
- platelet reactivity 959, 1123, 1127, 1132, 1134, 1135, 1137, 1140, 1144, 1148
 - on-treatment 1123, 1127, 1128, 1151

- reducing 1151
- residual 857
- platelet reactivity index (PRI)
 - 1124, 1129–1131
- platelets 411, 412, 1127, 1128,
 - 1137, 1143, 1144
 - newborn 1143
 - non-aspirin-inhibited 1146
 - reticulated 1143
 - young 1143
- polyethylene glycol (PEG) 10, 12,
 - 64, 67, 112, 115, 176, 177,
 - 1215, 1221, 1227
- polymerase chain reaction (PCR)
 - 135, 172, 262, 624, 625, 849,
 - 898, 972
- populations
 - bulk cell 28
 - community 1341
 - concrete 769
 - divergent 694
 - elderly veteran 374
 - employed 365
 - ethnic 350, 356, 376, 906
 - healthier 341
 - healthy 616, 617
 - high-risk 33
 - immune cell 1194
 - key 363, 1357
 - natural 326–328
 - non-Caucasian 357, 1351
 - normal 631, 930
 - older 343
 - orphan 816, 825, 831
 - pediatric 694, 830
 - virtual 714
- positive predictive value (PPV)
 - 673, 674, 847
- positron emission tomography (PET) 16, 83–85, 90, 91, 358,
 - 1182, 1189, 1393
- PPIs *see* proton pump inhibitors
- PPV *see* positive predictive value
- predictive models 195, 204, 208,
 - 214, 270, 630, 634, 635
- PRI *see* platelet reactivity index
- primary care physicians (PCPs)
 - 1360, 1367
- principal component analysis (PCA) 238, 239, 242, 244
- process analytical technology (PAT) 39
- processes
 - auditable 654
 - automates 1442
 - biochemical 899
 - biologic 1393
 - carrier-mediated 161
 - cellular 261, 270, 274, 282, 926,
 - 1307
 - clinical 1405
 - clinical evaluation 1295
 - clinical trial 825
 - comprehensive 211
 - computer-aided 905
 - continuous biological 324
 - correction 765
 - cyclical 793
 - death-mediated 133
 - degenerative 1339
 - documentation 210
 - double-emulsion 1221
 - drive 1424
 - drug release 130
 - evolutionary 206
 - exclusive 12
 - expensive 42
 - gene regulation 130
 - homogeneous 1297
 - increasing storage 729
 - interpretation 633
 - interrelated dynamic 913
 - intracellular 1143
 - iterative 664
 - key 931
 - knowledge-based 728
 - labor-intensive 1382

- molecular 1186
- multifactorial 1135
- multistep 1297, 1324
- painful 1410
- particular biological 282
- pathogenic 609, 1188
- pathological 31, 1220
- personalization 1187
- physiological 1203
- postmarketing surveillance 727, 728
- random 739
- reflective 838
- regulatory approval 800
- return-of-results 830
- sample management 653
- scientific 39, 660
- signaling 135
- successful optimization 1209
- systematic 1457, 1458
- tablet-manufacturing 144
- translational 196, 199
- transparent 632
- two-step 856
- profiles
 - adverse-effect 489
 - benefit-risk 609
 - blood lipid 1353
 - cellular 1255, 1263
 - clinical 766, 929, 1148
 - comprehensive biomarker 200
 - concentration-time 697
 - control drug release 9
 - drug dosage 905
 - environmental 816, 1185
 - greater bioavailability 917
 - patient's 770
 - time-action 1223
 - toxico-logical 121
- prognosis 15, 23, 88, 195, 200, 222, 248, 310, 313, 342, 609
- prostate-specific antigen (PSA) 21, 22
- proteins
 - activated 979
 - anchored 1200
 - basic 68
 - binding 264, 688, 1125
 - bioluminescent 99
 - carrier 1313
 - cell matrix 270
 - cell-penetrating 62
 - cellular 1307
 - corepressor 480
 - drug-resistant 162
 - effector 269, 270
 - endogenous 977
 - enzymatic 151
 - fluorescent 100
 - high-abundance 25, 26
 - high-molecular-weight 25
 - histone 615
 - inactive 442
 - intracellular platelet 1124
 - mature 361
 - microsomal 482, 700, 701
 - mutant 447
 - phosphorylated 53
 - plasma membrane 1258
 - red fluorescent 100
 - resistance-associated 1310
 - retinol-binding 68
 - therapeutical 1214
 - transmembrane 110, 851
 - transporter 151, 176, 692, 698, 702, 1309
 - unstable 446
- protocols 185, 231, 630, 653, 1343, 1441, 1442, 1446, 1456-1459, 1463
- clinical 670, 672
- data-sharing 733
- network 1371
- polyplex 132
- similar isolation 1255
- proton pump inhibitors (PPIs) 403, 418-422, 955, 962-964, 1145, 1355

- PSA *see* prostate-specific antigen
p-values 260, 270, 272, 274–276, 278
 kappa 275
 lower 274
 lower distribution 272
 pair-wise 275
- QALYs *see* quality-adjusted life-years
 QSARs *see* quantitative structure-activity relationships
 QTLs *see* quantitative trait loci
 quality-adjusted life-years (QALYs) 780, 781, 785–787, 789–792, 797, 802, 805, 855
 quantitative structure-activity relationships (QSARs) 156, 1209
 quantitative trait loci (QTLs) 327–329, 339
- randomized clinical trials (RCTs) 341, 342, 954, 960, 962, 998, 1447–1450, 1459
 rapid metabolizers (RMs) 344, 350, 351, 364, 625, 857, 956, 963
 RCTs *see* randomized clinical trials
 reactions 113, 135, 280, 325, 396, 400, 483, 491, 496, 497, 678, 818, 846
 allergic 624
 chemical 107
 detoxification 1304
 drug immunoallergic 1313
 enzymatic 282
 fatal drug 41
 fission 112
 hepatotoxic 1310
 infusion-related 851
 life-threatening 847
 negative emotional 1364
 receiver operating characteristic (ROC) 761, 1129–1131
 receptors 17, 67–69, 110, 264, 265, 281, 323, 324, 336, 354, 355, 410, 412, 959, 1142, 1143, 1150
 5-HT2 459
 5-HT2A 369
 acid-related orphan 1193
 anti-epidermal growth factor 116
 asialoglycoprotein 67
 cell surface 68, 72, 86
 cell surface peptide 85
 chemokine 70, 709
 collagen 1135
 dopamine D2 464
 folate 115, 120
 folic acid 1225
 glucocorticoid 254
 hormonal 85
 hormone 96, 618
 human epidermal growth factor 17, 621, 958
 intracellular estrogen 480
 melanocortin 1180
 modified 412
 opioid 488
 opionic acid 711
 platelet membrane 1125, 1128, 1137, 1140, 1142
 purinergic 1123, 1124
 sigma 69
 somatostatin 90
 targeting transferrin 68
 thrombin 1152
 thromboxane 1143
- recommendations
 evidence-based 1444
 formal 867
 general 1441, 1442
 personalized 1422

- practical 935
- research ethics 1354
- succinct 679
- tailored 1441, 1442
- weight-based dosage 710
- recovery, urinary 473
- regions
 - adjacent genome 247
 - bright 359
 - chromosomal 247
 - flanking 857
 - geographical 815
 - internal 135
 - intragenic 1312
 - key brain 1181
 - limbic 360
 - linker 135
 - nonhypoxic 119
 - prefrontal 360
 - promoter 352, 360, 1312
 - relevant 652
 - significant consensus 239
 - unique 181
 - various 1174
- release 23, 29, 45, 61, 62, 65, 132, 159, 697, 1173, 1175, 1200–1202, 1221, 1222
 - appropriate 29
 - controlled 12, 186
 - expanded 29
 - fast enzyme 132
 - liver enzyme 64
 - payload 66
 - preventing 10
 - proinflammatory cytokine 130
 - slow cytoplasmic 132
 - sustained 28
- renal failure 472, 752
- renal function 349, 363, 388, 954, 995, 998
- renal impairment 391, 689, 691, 701, 703
- reporting odds ratio (ROR) 738, 756, 760
- research
 - clinical 222, 252, 375, 610, 632, 829, 830, 1413, 1414
 - cost-effectiveness 794
 - distinct 794
 - ethical 837
 - experimental 1248
 - fish 641
 - fundamental 823
 - heterogeneous 208
 - intense 1194
 - life sciences 222
 - membrane transporter 930
 - observational 961
 - pharmacogenetic 337, 895, 899, 995
 - pharmacological 925
 - regulatory science 36, 37
 - requisite 608
 - retrospective 230
 - revive 40
 - significant 27, 635, 1263
 - whole-genome 1354
- research participants 816, 822, 824, 825, 828, 830, 831, 833, 836, 837
 - potential 824
 - sick 831
- residual platelet reactivity (RPR) 857
- resistance 42, 43, 69, 165, 167, 200, 672, 680, 1126–1128, 1149, 1196
 - clinical 485
 - docetaxel 76
 - multidrug 163, 908, 1140, 1310
 - neuronal 1196
 - obesity-insulin 1182
 - vascular 467
- reticulated platelets (RPs) 268, 1143
- reverse transcriptase (RT) 622

- ribonucleic acid (RNA) 14, 132, 173, 185, 231, 304, 426, 609, 616, 901, 1211
- ribonucleic acid interference (RNAi) 59, 60, 62, 901
- RISC *see* RNA-induced silencing complex
- risperidone 347, 348, 350, 356, 428, 459, 460, 462
- RMs *see* rapid metabolizers
- RNA *see* ribonucleic acid
- RNAi *see* ribonucleic acid interference
- RNA-induced silencing complex (RISC) 60
- ROC *see* receiver operating characteristic
- ROR *see* reporting odds ratio
- routes 13, 130, 133, 148, 465, 680, 686, 689, 692, 696, 1214, 1223, 1227, 1274, 1423
- active transport absorption 150
- biliary 702
- carrier-mediated 150
- inhalation dosing 705
- major 466, 471
- major metabolic 410, 454, 479, 485, 493
- most common 697
- multifaceted 129
- oral 142, 709, 1208, 1215
- paracellular 149, 150
- physiological 1213
- popular 141
- transcellular 148, 150, 1216
- RPR *see* residual platelet reactivity
- RPs *see* reticulated platelets
- RT *see* reverse transcriptase
- SAC *see* single adjusting compartment
- Saccharomyces Genome Database (SGD) 308, 318
- SAE *see* serious adverse event
- samples
- annotated 629
- biological 231, 628, 629, 905
- clinical 22, 24, 274
- clinical trial 654
- collected 822
- complex 25
- core needle biopsy 226
- diseased 173
- healthy 173
- hold-out 307
- human 273
- individual 175, 237
- labeled 172
- male 353
- patient's plasma 622
- patient virus 622
- phenotyped 1325
- saliva 1342, 1344
- storing 629
- tumor 42
- whole-blood 861, 1124
- SAR *see* statistical analysis report
- SCRs *see* significant consensus regions
- selective serotonin reuptake inhibitors (SSRIs) 211, 343, 345, 346, 350, 352, 354, 403, 422, 428, 454, 455, 1374
- selectivity 259, 1208, 1212
- increased molecular 12
- insufficient 1209
- intrinsic chemical 22
- observed tumor 114
- sensitivity 22–24, 131, 171, 185, 287, 364, 620, 673, 689, 729, 738, 741, 791, 848
- coumarine 975
- device 23
- femtomolar 21
- gemcitabine 188
- high 21, 99, 171, 383
- mammogram 24

- mice's 69
- model's 307
- systemic insulin 1198
 - test genetic 21
- sentinel lymph node (SLN) 97
- sequences 71, 135, 180, 201, 231, 299, 446, 646, 954, 1312
 - amino acid 426, 427, 600
 - biological 318
 - complementary nucleotide 60
 - conserved 70
 - leader 1308
 - microRNA 254
 - noncoding 389
 - noncoding RNA 1257
 - regulatory 385
- serendipity 660, 1209
- serious adverse event (SAE) 647
- serotonin 352, 430, 452, 453, 935, 957
 - human 368
 - mixed 456
 - selective 368
- SERS *see* surface-enhanced Raman scattering
- sertraline 346, 353, 358, 359, 403, 422, 454, 474, 980, 981, 983–987
- SGD *see* Saccharomyces Genome Database
- signal detection 729–731, 736, 738–740, 743, 744, 746, 754, 755, 760, 763, 769–771
- signals 32, 99, 635, 659, 728, 729, 739, 741, 758, 760, 761, 1174, 1198, 1227, 1283
 - adiposity-negative feedback 1196
 - biological 1217, 1218
 - danger 1313
 - detected 761
 - fluorescent 20
 - optical 100
 - peripheral 1191
 - pro-inflammatory 1257
 - signal-to-noise ratio 98
 - signatures
 - 70-gene 260, 618
 - breast cancer microarray 640
 - derived genes 261
 - distinct 261
 - gene-expression 640
 - heme-binding 446
 - median 266, 269
 - multiple 266, 279
 - robust 248
 - team's 275
 - significant consensus regions (SCRs) 239
 - single adjusting compartment (SAC) 695
 - single nucleotide polymorphisms (SNPs) 135, 353, 354, 356, 361, 362, 377, 378, 382, 384, 403, 407, 442, 497, 611, 612, 972, 1179, 1180
 - single-photon-emission computed tomography (SPECT) 16, 82, 84, 85, 91
 - SLN *see* sentinel lymph node
 - small intestine 142, 145, 146, 148–150, 152, 164, 1218
 - SMDB *see* Stanford Microarray Database
 - smoking 701, 769, 954, 993, 1142, 1344, 1359, 1383, 1393
 - SMQs *see* standardized MedDRA queries
 - SNALP *see* stable nucleic acid–lipid particle
 - SNOMED *see* Systematized Nomenclature of Medicine
 - SNPs
 - additional 407
 - critical 446
 - encountered 1322
 - frequent 1179
 - functional 360, 497

- intrinsic 445
- low-frequency 1188
- multiple 995, 998
- nonsynonymous 377, 382, 384, 389, 403, 431, 868
- SNPs *see* single nucleotide polymorphisms
- society 213, 632, 781, 785, 788, 797, 814, 894, 911, 937, 1187
 - contemporary 817
 - international AIDS 642
- SOCs
 - primary 735
 - secondary 735
- SOC *see* system organ class
- sources
 - allogeneic 1253, 1261
 - allogeneic stem cell 1254
 - cellular 1251
 - clinical 911
 - controversial 1261
 - disparate 222, 793
 - dynamic 932
 - excitation light 100
 - heterogeneous 204, 230
 - ideal 663
 - initial 663
 - laser 23
 - local 1290
 - mainstream 259
 - most potent cell 27
 - multiple 38, 1255, 1419
 - optimal sample 653
 - primary 1349, 1460
 - random 1284
 - unjustified 828
 - unrelated 926
- spaces
 - extracellular 110
 - interstitial 1213
 - interstitial tissue 1227
 - left anterior pararenal 93
 - low-dimensional Euclidean 305
 - multidimensional Euclidean 302
 - three-dimensional 235
 - two-dimensional 309
- sparteine 427–429, 443, 468, 476
- specificity 12, 17, 22, 24, 66, 68, 115, 259, 428, 476, 616, 652, 673, 741, 848
 - biological 14
 - high 465, 631
 - imperfect 172
 - low 738
 - molecular 16
 - nanoparticle 18
- SPECT *see* single-photon-emission computed tomography
- spectrum 19, 133, 238, 377, 424, 468, 1119, 1132, 1184, 1186, 1251, 1254, 1402, 1456
- Spontaneous Reporting System (SRS) 733, 739, 777
- SRS *see* Spontaneous Reporting System
- SSRIs *see* selective serotonin reuptake inhibitors
- stable nucleic acid–lipid particle (SNALP) 64, 67
- stakeholders 33, 230, 648, 668, 833, 834, 837, 876, 1188, 1407, 1415, 1420, 1426, 1427, 1429
 - external 646
 - individual 661
 - internal 651, 663
- standardized MedDRA queries (SMQs) 740–744, 764, 765
- standards 32, 36, 199, 201, 208, 209, 230, 231, 632, 656, 1412, 1414, 1415
 - clear 1422
 - clinical 834
 - coding 208
 - flexible 1412
 - highest ethical 1371

- international 1456, 1457, 1466
- interoperability 1403
- life sciences 1413
- tight 40
- traditional 646
- Stanford Microarray Database (SMDB) 250, 256
- statistical analysis 212, 691, 729, 741, 755, 756, 795, 799
- statistical analysis report (SAR) 679
- statistical approaches 175, 274, 676, 729, 739, 1280, 1285
- statistical methods 259, 280, 282, 305, 635
- statistical moments 1274
- statistical power 322, 634, 635, 712, 729, 792, 932, 1305, 1312, 1373
- stem cells 27, 28, 919, 1248–1261, 1263, 1338, 1339
 - adult neural 1251
 - autologous 1253
 - bone marrow 1257
 - healthy 1253
 - hematopoietic 1249
 - host 1253
 - most studied 1249
 - resident 1251
 - resident cardiac 1257
 - transplanted 1257
- stem cell therapy 30, 1248, 1249, 1253, 1260, 1262
- stent thrombosis 859, 959, 1141
- stomach 142, 145, 146, 164, 236, 419, 751, 975
- stromal vascular fraction (SVF) 1193
- substrates 20, 100, 151, 162, 164, 165, 345, 377, 378, 382, 383, 398, 399, 410, 411, 443–446, 470, 710, 1302, 1303, 1305, 1306
- common 164
- direct 151
- endogenous 99
- functionalized 19
- insulin receptor 1143
- labeled 1199
- natural 167
- neural 371
- poor 411
- probe 378, 383, 428, 444, 476, 723
- sulfonylureas 400–402, 1172, 1190
- support vector machine (SVM) 306, 308, 318
- surface 10, 28, 41, 65, 67, 69, 118, 171, 173, 1217, 1218, 1220, 1224
 - carrier 1224
 - charged 1217
 - coated 1217
 - cytoplasmic 1227
 - platelet 1135
 - solid 172, 173
- surface antigen 69
- surface area 36, 110, 143, 145
 - nonpolar 150
 - patient's body 874
 - polar 150
- surface-enhanced Raman scattering (SERS) 23
- surgery 227, 1205, 1344, 1393
 - abdominal 489
 - bariatric 1204
 - fluorescence-guided 100
- susceptibility genes 1009, 1176, 1179, 1182, 1186, 1206, 1207, 1211, 1212, 1225, 1228
- SVF *see* stromal vascular fraction
- SVM *see* support vector machine
- Systematized Nomenclature of Medicine (SNOMED) 741, 751, 752, 764, 775
- system organ class (SOC) 735, 736, 741–743, 750

- systems
 - administrative 1400, 1409
 - alert 767
 - bodily 5
 - body vascular 703
 - cardiovascular 97
 - cartridge-based 1125
 - cellular 687
 - clinical diagnosis 52
 - community health 1361
 - complex 311, 1150
 - control 714
 - defense 1217
 - departmental 1408
 - electronic 199, 1440, 1444, 1463
 - emblematic 13
 - endocrine 1174
 - error management 1463
 - homeostatic 1191
 - human 191, 192, 194
 - insurance 1409
 - integrated 715
 - integrative 208
 - interactive 298
 - interoperable 1373
 - liposomal 124
 - microarray 184
 - monoaminergic 352
 - multistage 13, 14
 - nanoparticulate 10
 - national 833, 912, 1354
 - nervous 121, 428, 470
 - neural 1191
 - pharmacy's 997
 - prototype 318
 - reproductive 272
 - retrieval 295
 - vendor's 1414
 - systems mapping 321–324, 326–334, 336–339
- tacrine 464, 465, 1307, 1311
- TDI *see* time-dependent inhibition
- TDM *see* therapeutic drug monitoring
- techniques
 - analytical 261
 - anonymization 824
 - basic 292
 - bedside 1119
 - electron microscopy 121
 - genomic partitioning 135
 - high-throughput 197
 - interactive visualization 234
 - invasive 24
 - microarray 204
 - natural language 307
 - nineteenth-century 1420
 - silico 161
 - silicon nanofabrication 22
 - statistical 292
- technologies
 - advanced 203
 - automation 708
 - computer-based 686
 - cutting-edge 313
 - engineering 27
 - genetic health 800
 - inkjet 173
 - microarray 19, 20, 175, 178, 181, 183, 231
 - planar 82
 - proteomic 618
 - semantic 911
 - semiconductor 232
- TEG *see* thromboelastography
- terminological reasoning (TR) 404, 744, 747, 754–763
- TFs *see* transcription factors
- therapeutic agents 13, 121, 130, 162, 497
- therapeutic drug monitoring (TDM) 423, 495, 496, 928, 933, 957, 996, 1272, 1273, 1276, 1289

- therapeutic drugs 164, 375, 965, 966, 1302, 1304
- therapeutic effects 60, 69, 393, 416, 451, 455, 462, 870, 1262
- therapeutic efficacy 9, 45, 130, 393, 402, 917, 922
- therapeutic interventions 99, 608, 609, 1188, 1190, 1194, 1383, 1385, 1387
- therapeutic proteins 695, 1172, 1213, 1216, 1222, 1224
- therapeutic response 42, 92, 99, 194, 200, 343, 355, 386
- therapy
 - allogeneic 1253
 - anticancer 19
 - anticancer-targeted 1455
 - antidepressant 342, 353
 - antiemetic 998
 - anti-HIV 78
 - antihypertensive 57
 - antiplatelet 1148, 1153
 - autologous transplant 1253
 - boron-facilitated 113
 - cell-based 1248, 1259, 1262
 - cellular 1248
 - cetuximab 612, 639
 - chronic 1452
 - concomitant 767
 - nitrogen mustard 4
 - nucleic acid 137
 - one-size-fits-all 8
 - pharmacologic 364
 - radionuclide 90
 - regenerative 1250
 - valproate 621
- thiopurine drugs 626, 970
- thioridazine 345, 348, 428, 443, 444, 458, 463, 474
- thromboelastography (TEG) 1127, 1128, 1133
- ticlopidine 410, 411, 1131
- time-dependent inhibition (TDI) 709
- tissues
 - adult 27, 1251
 - biological 101
 - cancerous 65, 66
 - cardiovascular 27, 54
 - colon 206
 - connective 63, 1251
 - damaged 27, 1256
 - diseased 134, 927, 1224
 - extrahepatic 376
 - healthy 27
 - insulin-sensitive 1190, 1194
 - invasive 854
 - load-bearing 29
 - passive 65
 - peripheral 1195
 - subcutaneous 62
- TLRs *see* toll-like receptors
- TNF *see* tumor necrosis factor
- tolbutamide 378, 382, 395, 399–401, 989
- toll-like receptors (TLRs) 61
- tools
 - analytic 236
 - building 1410
 - clinical therapeutic 62
 - computer support 1446
 - decision-making 251
 - dose calculator 1459
 - easy-to-use 929
 - efficient drug prescription 912
 - electronic support 1440
 - exploration 657
 - generation terminology 777
 - immunoinformatics 211
 - methodological 814
 - statistical signal detection 736
 - therapeutic 70
 - third-party 241, 242
 - twenty-first-century 1420
- torasemide 378, 393
- toxicity
 - cardiovascular 458
 - cellular 132

- digitoxin 165
- embryo-fetal 851
- hematologic 614
- high-throughput 131
- intrinsic 1297
- long-term 1216
- pulmonary 851
- systemic 75
- tamoxifen-induced 482
- xenobiotic-induced 270
- TR *see* terminological reasoning
- tramadol 428, 429, 488–490, 957, 958, 1303
- transcription factors (TFs) 67, 206, 244, 264, 265, 269, 279, 281, 1211, 1213
- translational bioinformatics 136, 191–193, 195–201, 204, 205, 207–215
- translational medicine 192
- translational research 95, 208, 248, 1203
- transporters 162, 163, 168, 169, 176, 186–188, 207, 284, 352, 694, 702, 703, 766, 922, 923, 1140, 1310
- choline 168
- concentrative nucleoside 167
- equilibrative nucleoside 167
- influx 150
- intracellular 162
- neurotransmitter 162, 352
- oligopeptide 908
- organic anion 908
- peptide 162
- secondary active 162
- trastuzumab 7, 41, 91, 619, 621, 846, 850–855, 875, 958, 1393
- trial design 689, 693, 696, 789, 798
- trials
 - adaptive research 1420
 - government-funded public 364
 - large placebo-controlled 859
 - pharmacological 326
 - postmarketing 653
 - prospective genetic 624
- tropisetron 429, 479, 480
- tumor necrosis factor (TNF) 70, 904, 1257, 1313
- tumors 10, 11, 13, 19, 24, 41, 42, 89–91, 97, 98, 118, 119, 168, 958, 959, 1218–1221, 1227, 1260, 1261
 - colon-26 116
 - colorectal 959
 - early-stage 615
 - endocrine 90
 - lobular 226
 - mice's subcutaneous 67
 - mouse colon 189
 - neck 113
 - neural crest 90
 - ovarian 14
 - solid 9, 68, 116, 1220
 - transplanted 67
- UCDs *see* urea cycle disorders
- UDP-glucuronosyl transferase (UGT) 394, 413, 414, 460, 486, 487, 627, 674, 862, 863, 975–977, 1306
- UGT *see* UDP-glucuronosyl transferase
- ultrarapid metabolizers (UMs) 344, 345, 348, 350, 351, 364, 430, 457, 477, 478, 488–490, 857, 858, 860, 861, 863–865, 956, 958, 968, 1141
- UML *see* Unified Modeling Language
- UMs *see* ultrarapid metabolizers
- Unified Modeling Language (UML) 210, 219
- UPT *see* User Provisioning Tool
- urea cycle disorders (UCDs) 621
- User Provisioning Tool (UPT) 242

- variants
 - cryptic splice 1141
 - diminished-function 353
 - fVL 979
 - haplotype 384
 - homozygous TT 873
 - multiple 625, 1326
 - penetrant 1178
 - polymorphic 1307
 - rare 1179, 1180
- variations
 - diurnal 1203
 - epigenetic 633
 - genetic sequence 213
 - heritable 613
 - interethnic 410, 497
 - interpatient 458
 - person-to-person 1262
 - quantitative 1194
 - sequence 180, 184
 - stable 377
 - structural 193
- vascular endothelial growth factor (VEGFs) 21, 1227, 1257
- vectors 299, 300, 302, 303, 327, 330, 1277, 1280, 1284
 - carrier 16
 - computer-readable numeric 304
 - gene delivery 1225
 - hybrid 137
 - logic-embedded 12
 - multistage silicon 14
 - nonviral gene 1226
 - q -dimensional 325
 - viral 60, 1207, 1226
- vector space model (VSM) 298, 299, 301
- VEGFs *see* vascular endothelial growth factor
- venlafaxine 346, 358, 359, 428, 431, 443, 445, 456–458, 936
- ventricular arrhythmias 345, 473, 475
- virus 182, 622, 624, 1225, 1299
 - human immunodeficiency 23, 70, 416, 611, 709, 846
 - noninfectious 416
- VSM *see* vector space model

- warfarin
 - anticoagulant 612
 - blood thinner 1374
 - coumarin 961
- warfarin dose 388, 597, 869, 872
- warfarin therapy 387, 388, 626
- WAT *see* white adipose tissue
- weighted least squares (WLS) 1278, 1283
- WGS *see* whole-genome sequencing
- white adipose tissue (WAT) 1175, 1193, 1194, 1197–1200
- whole-genome sequencing (WGS) 998, 1179, 1188, 1324, 1325, 1345, 1356, 1357, 1368
- WLS *see* weighted least squares